Document and Entity Information	12 Months Ended
Document and Entity Information	Mar. 31, 2014
Document and Entity Information
Document Type	20-F
Amendment Flag	false
Document Period End Date	Mar. 31, 2014
Entity Registrant Name	China Cord Blood Corp
Entity Central Index Key	0001467808
Trading Symbol	CO
Current Fiscal Year End Date	--03-31
Document Fiscal Year Focus	2014
Document Fiscal Period Focus	FY
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding	73,003,248
Entity Well-known Seasoned Issuer	No
Entity Current Reporting Status	Yes

Consolidated Balance Sheets In Thousands, unless otherwise specified	Mar. 31, 2014 USD ($)	Mar. 31, 2014 CNY	Mar. 31, 2013 CNY
Current assets
Cash and cash equivalents	$ 302,892	1,882,901	1,494,099
Accounts receivable, less allowance for doubtful accounts (March 31, 2013: RMB14,112; March 31, 2014: RMB20,322 (US$3,269))	15,326	95,273	73,076
Inventories	5,080	31,583	10,265
Prepaid expenses and other receivables	5,954	37,010	11,602
Debt issuance costs	582	3,616	3,678
Deferred tax assets	1,233	7,664	5,454
Total current assets	331,067	2,058,047	1,598,174
Property, plant and equipment, net	100,804	626,632	468,272
Non-current prepayments	33,604	208,894	212,633
Non-current accounts receivable, less allowance for doubtful accounts (March 31, 2013: RMB36,361; March 31, 2014: RMB42,703 (US$6,869))	36,275	225,496	249,370
Inventories	7,783	48,385	39,730
Intangible assets, net	19,392	120,549	125,170
Available-for-sale equity securities	23,204	144,247	88,404
Other investment	30,424	189,129	189,129
Debt issuance costs	1,263	7,854	11,667
Deferred tax assets	288	1,789	3,727
Total assets	584,104	3,631,022	2,986,276
Current liabilities
Bank loan	9,652	60,000	50,000
Accounts payable	1,677	10,422	9,890
Accrued expenses and other payables	16,498	102,559	84,006
Deferred revenue	31,599	196,432	172,328
Amounts due to related parties	3,452	21,453	11,241
Income tax payable	414	2,571	4,983
Deferred tax liabilities	627	3,900
Total current liabilities	63,919	397,337	332,448
Convertible notes	125,113	777,753	751,781
Non-current deferred revenue	132,540	823,921	530,258
Other non-current liabilities	26,395	164,077	107,158
Deferred tax liabilities	4,494	27,938	23,168
Total liabilities	352,461	2,191,026	1,744,813
Shareholders' equity of China Cord Blood Corporation
Ordinary shares - US$0.0001 par value, 250,000,000 shares authorized, 73,140,147 shares issued and 73,003,248 shares outstanding as of March 31, 2013 and 2014, respectively	8	50	50
Additional paid-in capital	128,405	798,221	798,221
Treasury stock, at cost (March 31, 2013 and 2014: 136,899 shares, respectively)	(453)	(2,815)	(2,815)
Accumulated other comprehensive income	13,555	84,263	18,256
Retained earnings	89,331	555,323	423,420
Total equity attributable to China Cord Blood Corporation	230,846	1,435,042	1,237,132
Non-controlling interests	797	4,954	4,331
Total equity	231,643	1,439,996	1,241,463
Commitments and contingencies
Total liabilities and equity	$ 584,104	3,631,022	2,986,276

Consolidated Balance Sheets (Parenthetical) In Thousands, except Share data, unless otherwise specified	Mar. 31, 2014 USD ($)	Mar. 31, 2014 CNY	Mar. 31, 2013 USD ($)	Mar. 31, 2013 CNY
Consolidated Balance Sheets
Accounts receivable, allowance for doubtful accounts	$ 3,269	20,322		14,112
Non-current accounts receivable, allowance for doubtful accounts	$ 6,869	42,703		36,361
Ordinary shares, par value per share	$ 0.0001		$ 0.0001
Ordinary shares, shares authorized	250,000,000	250,000,000	250,000,000	250,000,000
Ordinary shares, shares issued	73,140,147	73,140,147	73,140,147	73,140,147
Ordinary shares, shares outstanding	73,003,248	73,003,248	73,003,248	73,003,248
Treasury stock, shares	136,899	136,899	136,899	136,899

Consolidated Statements of Comprehensive Income In Thousands, except Per Share data, unless otherwise specified	12 Months Ended
	Mar. 31, 2014 USD ($)	Mar. 31, 2014 CNY	Mar. 31, 2013 CNY	Mar. 31, 2012 CNY
Consolidated Statements of Comprehensive Income
Revenues	$ 92,152	572,857	526,123	380,490
Direct costs	(17,088)	(106,225)	(106,621)	(86,658)
Gross profit	75,064	466,632	419,502	293,832
Operating expenses
Research and development	(1,572)	(9,773)	(8,459)	(7,615)
Sales and marketing	(18,128)	(112,689)	(93,684)	(61,678)
General and administrative	(18,056)	(112,244)	(108,045)	(89,696)
Total operating expenses	(37,756)	(234,706)	(210,188)	(158,989)
Operating income	37,308	231,926	209,314	134,843
Other income/(expense), net
Interest income	2,714	16,870	15,064	13,432
Interest expense	(11,273)	(70,075)	(70,097)	(3,287)
Exchange (loss)/gain	13	80	(984)	(1,343)
Dividend income	1,594	9,911	4,685	7,217
Others	356	2,212	203	737
Total other income/(expense), net	(6,596)	(41,002)	(51,129)	16,756
Income before income tax	30,712	190,924	158,185	151,599
Income tax expense	(9,394)	(58,398)	(38,543)	(9,634)
Net income	21,318	132,526	119,642	141,965
Net income attributable to non-controlling interests	(100)	(623)	(7,195)	(9,985)
Net income attributable to China Cord Blood Corporation's shareholders	21,218	131,903	112,447	131,980
Net income per share: Attributable to ordinary shares
Basic	$ 0.26	1.60	1.49	1.79
Diluted	$ 0.26	1.60	1.49	1.79
Other comprehensive income
Net effect of foreign currency translation, net of nil tax	1,335	8,299	1,296	(1,653)
Net unrealized gain/(loss) in available-for-sale equity securities, net of nil tax	9,283	57,708	(9,120)	46,587
Comprehensive income	31,936	198,533	111,818	186,899
Comprehensive income attributable to non-controlling interests	(100)	(623)	(7,172)	(10,282)
Comprehensive income attributable to China Cord Blood Corporation's shareholders	$ 31,836	197,910	104,646	176,617

Consolidated Statements of Comprehensive Income (Parenthetical) (CNY) In Thousands, unless otherwise specified	12 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2012
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent
Net effect of foreign currency translation, tax	0	0	0
Net unrealized gain/(loss) in available-for-sale equity securities, tax	0	0	0

Consolidated Statement of Changes in Equity In Thousands, except Share data	Total USD ($)	Total CNY	Share capital USD ($)	Share capital CNY	Additional paid-in Capital USD ($)	Additional paid-in Capital CNY	Treasury stock USD ($)	Treasury stock CNY	Accumulated other comprehensive (loss)/income USD ($)	Accumulated other comprehensive (loss)/income CNY	Retained earnings USD ($)	Retained earnings CNY	Non-controlling interests USD ($)	Non-controlling interests CNY
Balance at Mar. 31, 2011		1,093,392		52		910,316				(18,580)		178,993		22,611
Balance, shares at Mar. 31, 2011		75,406,875		75,406,875
Net income		141,965										131,980		9,985
Other comprehensive income		44,934								44,637				297
Repurchase and cancellation of shares		(44,664)		(2)		(44,662)
Repurchase and cancellation of shares, shares		(2,266,728)		(2,266,728)
Balance at Mar. 31, 2012		1,235,627		50		865,654				26,057		310,973		32,893
Balance, shares at Mar. 31, 2012		73,140,147		73,140,147
Net income		119,642										112,447		7,195
Other comprehensive income		(7,824)								(7,801)				(23)
Repurchase of shares		(131,302)						(131,302)
Repurchase of shares, shares		(7,450,914)						(7,450,914)
Sale of treasury shares		131,828				3,341		128,487
Sale of treasury shares, shares		7,314,015						7,314,015
Acquisition of non-controlling interests		(106,508)				(70,774)								(35,734)
Balance at Mar. 31, 2013		1,241,463		50		798,221		(2,815)		18,256		423,420		4,331
Balance, shares at Mar. 31, 2013		73,003,248		73,140,147				(136,899)
Net income	21,318	132,526										131,903		623
Other comprehensive income		66,007								66,007
Balance at Mar. 31, 2014	$ 231,643	1,439,996	$ 8	50	$ 128,405	798,221	$ (453)	(2,815)	$ 13,555	84,263	$ 89,331	555,323	$ 797	4,954
Balance, shares at Mar. 31, 2014	73,003,248		73,140,147				(136,899)

Consolidated Statements of Cash Flows In Thousands, unless otherwise specified	12 Months Ended
	Mar. 31, 2014 USD ($)	Mar. 31, 2014 CNY	Mar. 31, 2013 CNY	Mar. 31, 2012 CNY
Operating activities:
Net income	$ 21,318	132,526	119,642	141,965
Adjustments to reconcile net income to net cash provided by operating activities:
(Gain)/loss on disposal of property, plant and equipment	(5)	(32)	1,066	(112)
Depreciation of property, plant and equipment	5,219	32,444	31,253	24,736
Amortization of intangible assets	743	4,621	4,621	4,621
Deferred income taxes	1,351	8,398	(194)	(4,771)
Provision for doubtful accounts	2,891	17,973	7,468	12,588
Interest on convertible notes	2,226	13,835	26,791
Amortization of debt issuance costs	581	3,610	3,062
Changes in operating assets and liabilities:
Non-current prepayments	43	261	1,513	3,408
Accounts receivable	(2,621)	(16,296)	3,334	(27,482)
Inventories	(4,822)	(29,973)	(8,678)	(2,988)
Prepaid expenses and other receivables	(4,093)	(25,441)	(3,470)	(1,673)
Accounts payable	86	532	3,547	1,297
Accrued expenses and other payables	1,775	11,036	42,080	9,441
Deferred revenue	51,118	317,767	289,942	167,657
Other non-current liabilities	9,128	56,745	46,380	30,384
Amounts due to related parties	1,676	10,421	10,881
Income tax payable	(388)	(2,412)	(960)	(5,213)
Trading securities			354
Net cash provided by operating activities	86,226	536,015	578,632	353,858
Investing activities:
Purchase of property, plant and equipment	(24,145)	(150,093)	(226,241)	(43,114)
Purchase of intangible assets				(80,188)
Investment deposit			(213,160)
Proceeds from disposal of property, plant and equipment	34	210	450	357
Acquisition of other investment			(54,766)
Net cash used in investing activities	(24,111)	(149,883)	(493,717)	(122,945)
Financing activities:
Repayment of bank loan	(8,043)	(50,000)	(45,000)	(45,000)
Proceeds from bank loan	9,652	60,000	50,000	45,000
Payment for repurchase of shares	(711)	(4,422)	(126,819)	(44,664)
Net proceeds from sale of treasury stock and acquisition of non-controlling interests			25,320
Proceeds from issuance of convertible notes			730,493
Payment of debt issuance costs	(522)	(3,242)	(15,276)
Net cash (used in)/provided by financing activities	376	2,336	618,718	(44,664)
Effect of foreign currency exchange rate change on cash and cash equivalents	54	334	(3,845)	(3,325)
Net increase in cash and cash equivalents	62,545	388,802	699,788	182,924
Cash and cash equivalents at beginning of year	240,347	1,494,099	794,311	611,387
Cash and cash equivalents at end of year	302,892	1,882,901	1,494,099	794,311
Non-cash investing and financing activities:
Payable for property, plant and equipment	6,604	41,055	1,675
Payable for share repurchases			4,483
Payable for debt issuance costs			3,242
Supplemental disclosures of cash flow information:
Cash paid during the year for income taxes	10,405	64,683	40,105	30,051
Cash refund during the year for income taxes	69	429	408	10,433
Cash paid for interest, net of capitalized interest	$ 4,520	28,096	3,512	3,287

Principal activities, reorganization and reverse recapitalization, and basis of presentation	12 Months Ended
	Mar. 31, 2014
Principal activities, reorganization and reverse recapitalization, and basis of presentation
Principal activities, reorganization and reverse recapitalization, and basis of presentation	1 Principal activities, reorganization and reverse recapitalization, and basis of presentation *(a)* *Principal activities* China Cord Blood Corporation (the “Company”) and its subsidiaries (collectively the “Group”) are principally engaged in the provision of umbilical cord blood storage and ancillary services in the People’s Republic of China (the “PRC”). As of March 31, 2014, the Group has three operating cord blood banks in the Beijing municipality, the Guangdong province and the Zhejiang province, the PRC. The Company’s shares are listed on the New York Stock Exchange. The Group provides cord blood testing, processing and storage services under the direction of subscribers for a cord blood processing fee and a storage fee. The Group also tests, processes and stores donated cord blood, and provides matching services to the public for a fee. The operation of cord blood banks in the PRC is regulated by certain laws and regulations. Cord blood banks in the PRC are required to possess a Blood Station Operation License. The licensing process for a cord blood bank is stringent and lengthy. The government authorities grant Blood Station Operation Licenses to cord blood banks that provide cord blood banking services. Cord blood banks collecting cord blood units from donors and providing matching cord blood units to the public without a duly obtained Blood Station Operation License face the risk of being shut down by the government. Seven cord blood banking licenses have been issued by the authorities as of March 31, 2014, of which the Company holds three. Due to the lack of a consistent and well-developed regulatory framework, operation in the cord blood banking industry in the PRC involves significant ambiguities, uncertainties and risks. The industry is highly regulated and any unilateral changes in regulations by the authorities may have a significant adverse impact on the Group’s results of operations. *(b)* *Reorganization and reverse recapitalization* The Company was previously named Pantheon China Acquisition Corp. (“Pantheon”), a blank check company whose objective was to acquire, through a stock exchange, asset acquisition or other similar business combination, an operating business that has its principal operations located in the PRC, or control such operating business through contractual arrangements. On November 3, 2008, China Cord Blood Services Corporation (“CCBS”) and its shareholders executed a Share Exchange Agreement with the Company. Pursuant to the Share Exchange Agreement, shareholders of CCBS were entitled to exchange their shares in CCBS for up to 57,851,240 shares of common stock of the Company. Shareholders holding 100% and 76% of CCBS’s ordinary shares and redeemable ordinary shares (collectively the “Participating Shareholders”), respectively, executed the Share Exchange Agreement and agreed to sell their 93.94% equity interests in CCBS to the Company for a consideration of US$328,790 in exchange for 54,345,104 shares of common stock of the Company (valued at US$6.05 per share of common stock) (the “Share Exchange”). The Share Exchange was approved at the Company’s special meeting of shareholders held on June 29, 2009 and was completed on June 30, 2009. Upon completion of the Share Exchange, the Company was renamed China Cord Blood Corporation and the Company was redomiciled to the Cayman Islands. The 54,345,104 shares of common stock of the Company held by the Participating Shareholders represent 91.7% of the then outstanding shares of the Company upon completion of the Share Exchange. Further, management of CCBS continued as the majority of the senior management of the Company upon completion of the Share Exchange. CCBS was therefore treated as the accounting acquirer in the Share Exchange. Prior to the Share Exchange, the Company did not operate a business. The Share Exchange was thus accounted for as the issuance of securities by CCBS in exchange for the assets and liabilities of Pantheon, accompanied by a recapitalization to utilize the share structure of Pantheon as the legal acquirer. In August 2009, the Company entered into agreements to exchange 3,506,136 of its newly issued ordinary shares for the remaining 24% of redeemable shares of CCBS held by shareholders who previously elected not to participate in the Share Exchange, on terms substantially similar to those of the Share Exchange. Upon the completion of such exchange, all the remaining redeemable ordinary shares of CCBS converted into ordinary shares of the Company, which carry no redemption rights, and CCBS became a wholly owned subsidiary of the Company. CCBS was incorporated in the Cayman Islands in January 2008 under the Cayman Islands Companies Law as an exempted company with limited liability. CCBS was incorporated as part of the reorganization of China Stem Cells Holdings Limited (“CSC Holdings”), which had two main operating subsidiaries in the PRC, Beijing Jiachenhong Biological Technologies Co., Ltd. (“Beijing Jiachenhong”) and Guangzhou Municipality Tianhe Nuoya Bio-engineering Co., Ltd. (“Guangzhou Nuoya”) at the time of the reorganization. Beijing Jiachenhong was established under the laws of the PRC in June 2001 as a domestic limited liability company. It became a Sino-Foreign Investment Enterprise in September 2003 and became a Wholly Foreign Owned Enterprise (“WFOE”) in March 2005. Beijing Jiachenhong is engaged in the provision of umbilical cord blood storage and ancillary services in the Beijing municipality, the PRC. In May 2007, China Stem Cells (South) Company Limited (“CSC South”), a 90% subsidiary of the Group, acquired the entire equity interest of Guangzhou Nuoya for consideration of RMB30,949. Guangzhou Nuoya was established under the laws of the PRC in June 1997 as a domestic limited liability company. It became a WFOE in May 2007. Guangzhou Nuoya has been granted the right to operate cord blood banks in the Guangdong province, the PRC. In November 2012, CSC South repurchased 10% of its shares from Cordlife (Hong Kong) Limited, a subsidiary of Cordlife Group Limited (“CGL”), at a consideration of US$16.8 million. The shares repurchased were subsequently cancelled. The difference between the consideration paid and the carrying amount of non-controlling interest equal to RMB70,774 at the repurchase date was charged to additional paid-in capital. Concurrently, CGL acquired 7,314,015 shares, which were held by the Company as treasury stock (representing 10% of the Company’s ordinary shares at the time of the transaction) at a consideration of US$20.8 million. The difference between the consideration received from sale of the shares over the cost of the treasury shares equal to RMB3,341 was credited to additional paid-in capital. As a result, the Company received a net proceed of US$4 million (RMB25,320) from the above two transactions and CSC South and its subsidiary became wholly owned subsidiaries of the Group. In December 2010, a non-wholly owned subsidiary, Zhejiang Lukou Biotechnology Co., Ltd. (“Zhejiang Lukou”), was established. The Group holds a 90% equity interest in Zhejiang Lukou through capital injection of RMB45,000, while the non-controlling shareholders contributed plant and equipment with fair value of RMB5,000 in return for the remaining 10% equity interests. In February, 2011, the Group acquired the right to operate the cord blood bank in the Zhejiang province, the PRC, from a third party at a consideration of US$12.5 million (equivalent to RMB82,124 (Note 8)). *(c)* *Basis of presentation* The accompanying consolidated financial statements have been prepared in accordance with U.S. Generally Accepted Accounting Principles (“U.S. GAAP”). This basis of accounting differs in certain material respects from that used for the preparation of the statutory books of the Company’s consolidated subsidiaries, which are prepared in accordance with the accounting principles and the relevant financial regulations applicable in the place of domicile of the respective entities in the Group. The accompanying consolidated financial statements reflect necessary adjustments not recorded in the statutory books of account of the Company’s consolidated subsidiaries to present them in conformity with U.S. GAAP.

- Definition

The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.

+ References+ Details

Summary of significant accounting policies

12 Months Ended

Mar. 31, 2014

Summary of significant accounting policies

Summary of significant accounting policies

2 Summary of significant accounting policies

(a) Principles of consolidation

The accompanying consolidated financial statements include the financial statements of the Company and its majority-owned subsidiaries. For consolidated subsidiaries where the Company’s ownership is less than 100%, the outside shareholders’ interests are shown as non-controlling interests. All significant intercompany balances and transactions have been eliminated in consolidation. The Company has no involvement with variable interest entities.

(b) Use of estimates

The preparation of the consolidated financial statements, in accordance with U.S. GAAP, requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant items subject to such estimates and assumptions include the establishment of the selling prices of multiple deliverables in revenue arrangements, the estimation of direct costs for the provision of donated cord blood for transplantation and research, the useful lives of property, plant and equipment and intangible assets, the valuation of property, plant and equipment, intangible assets and investment securities, the valuation allowances for receivables and deferred tax assets and the realizability of inventories.

(c) Foreign currency transactions and translation

The reporting currency of the Company is Renminbi (“RMB”).

The functional currency of Beijing Jiachenhong, Guangzhou Nuoya and Zhejiang Lukou is Renminbi (“RMB”) and the functional currency of the Company is United States dollars (“US$”). The functional currencies of subsidiaries of the Group outside the PRC are either US$ or Hong Kong dollars.

Transactions of Beijing Jiachenhong, Guangzhou Nuoya and Zhejiang Lukou denominated in currencies other than RMB are translated into RMB at the exchange rates quoted by the People’s Bank of China (the “PBOC”) prevailing at the dates of the transactions. Monetary assets and liabilities denominated in foreign currencies are translated into RMB using the applicable exchange rates quoted by the PBOC at the balance sheet date. The resulting exchange differences are recorded in the consolidated statements of comprehensive income.

Transactions of the Company and subsidiaries outside the PRC denominated in currencies other than their functional currencies are translated into their functional currencies at the exchange rates prevailing at the dates of the transactions. Monetary assets and liabilities denominated in foreign currencies are translated into their functional currencies using the applicable exchange rates at the balance sheet date. The resulting exchange differences are recorded in the consolidated statements of comprehensive income.

Assets and liabilities of the Company and subsidiaries outside the PRC are translated into RMB using the exchange rate at the balance sheet date. Revenues and expenses are translated at the average exchange rates prevailing during the year. The adjustments resulting from translation of financial statements of the Company and subsidiaries outside the PRC are recorded as a separate component of accumulated other comprehensive income within shareholders’ equity.

RMB is not a fully convertible currency. All foreign exchange transactions involving RMB must take place either through the PBOC or other institutions authorized to buy and sell foreign exchange. The exchange rates adopted for the foreign exchange transactions are the rates of exchange quoted by the PBOC, which are determined largely by supply and demand.

For the convenience of the readers, certain amounts as of and for the year ended March 31, 2014 included in the accompanying consolidated financial statements have been translated into U.S. dollars at the rate of US$1.00 = RMB6.2164, being the spot exchange rate of U.S. dollars in effect on March 31, 2014 for cable transfers in RMB per U.S. dollar as certified for customs purposes by the Federal Reserve, the central bank of the United States of America. No representation is made that the RMB amounts could have been, or could be, converted into U.S. dollars at that rate or at any other rate on March 31, 2014 or at any other date.

(d) Cash and cash equivalents

Cash and cash equivalents include short-term, highly liquid investments with original maturities of three months or less. Cash and cash equivalents of the Group are mainly maintained in the PRC and are denominated in several currencies. As of March 31, 2013 and 2014, cash and cash equivalents maintained in the PRC amounted to RMB1,470,844 and RMB1,812,007 (US$291,488), respectively. A majority of the Group’s cash and cash equivalents are denominated in U.S. dollars, Australian dollars, Renminbi, Hong Kong dollars and Singapore dollars as follows:

	March 31,
	2013		2014
	Foreign currency	RMB	Foreign currency	RMB
U.S. dollars	1,451	9,012	398	2,474
Australian dollars	137	895	242	1,378
Renminbi	1,469,512	1,469,512	1,812,025	1,812,025
Hong Kong dollars	17,820	14,542	81,188	64,503
Singapore dollars	27	138	515	2,521

Cash and cash equivalents held at financial institutions located in the PRC are uninsured, whereas cash held at financial institutions in Hong Kong are insured up to certain amount. Management believes that these major financial institutions have high credit ratings.

(e) Investment securities

Management determines the appropriate classification of its investment securities at the time of purchase and reevaluates such designations at each reporting date.

Available-for-sale equity securities are recorded at fair value. Unrealized holding gains and losses, net of the related tax effect, on available-for-sale equity securities are excluded from earnings and are reported as a separate component of accumulated other comprehensive income until realized. Realized gains and losses from the sale of available-for-sale equity securities are determined on a specific-identification basis. Where the fair value of an investment in equity securities is not readily determinable, the investment is stated at cost.

A decline in the market value of investment securities that is deemed to be other-than-temporary results in an impairment to reduce the carrying amount to fair value. The impairment is charged to earnings and a new cost basis for the security is established. In determining whether an impairment is other-than-temporary, the Company considers whether it has the ability and intent to hold the investment until a market price recovery and considers whether evidence indicating the cost of the investment is recoverable outweighs evidence to the contrary. Evidence considered in this assessment includes the reasons for the impairment, the severity and duration of the impairment, changes in value subsequent to year-end, forecasted performance of the investee, and the general market condition in the geographic area or industry the investee operates in.

Dividend income is recognized in other income when earned.

(f) Accounts receivable

Accounts receivable represent amounts due from subscribers for cord blood processing and storage services, which are recognized in accordance with the Company’s revenue recognition policies (Note 2(k)). Installments receivable from subscribers which are due for repayment in over one year under deferred payment options are classified as non-current accounts receivable. Accounts receivable are stated net of allowance for doubtful accounts.

The allowance for doubtful accounts is the Group’s best estimate of the amount of estimated losses in the Group’s existing accounts receivable. The Group determines the allowance based on historical write-off experience, customer specific facts and economic conditions.

The Group reviews its allowances for doubtful accounts quarterly. Outstanding account balances are reviewed on a pooled basis by ageing of such balances. Account balances are charged off against the allowance after all means of collection have been exhausted and the potential for recovery is considered remote. The Group’s PRC subsidiaries are required to comply with local tax requirements on the write-offs of doubtful accounts, which allow for such write-offs only when the related account balances are aged over three years and sufficient evidence is available to prove the debtor’s inability to make payments. For financial reporting purposes, the Group’s PRC subsidiaries generally record write-offs of doubtful accounts at the same time the local tax requirements for the write-offs are met. As a result, there are generally time lags between the time when a provision for doubtful accounts is recorded and the time the doubtful accounts are written off against the related allowance. The Group does not have any off-balance-sheet credit exposure related to its customers.

(g) Inventories

The Group collects, tests, freezes and stores donated umbilical cord blood for future transplantation or research purposes in return for a fee. Collection, testing and processing costs attributable to the processing of donated umbilical cord blood are capitalized as inventories, stated at the lower of cost or market on a weighted-average basis, and recognized as direct costs when revenue is recognized upon shipment of the donated cord blood units. Cost comprises direct materials, direct labor and an allocation of production overheads. Inventories that are not expected to be realized within 12 months from the balance sheet date are classified as non-current assets. Consumables and supplies are classified as current assets.

(h) Property, plant and equipment

Property, plant and equipment are stated at cost less accumulated depreciation.

Depreciation on property, plant and equipment is calculated based on the straight-line method (after taking into account their respective estimated residual values) over the estimated useful lives of the assets as follows:

Buildings	37.5 – 50 years
Leasehold improvements	Shorter of the lease term or estimated useful lives of 10 years
Machineries	5 – 10 years
Motor vehicles	5 years
Furniture, fixtures and office equipment	3 – 5 years

No depreciation expense is provided in respect of construction-in-progress.

Interest expense incurred related to the construction of property, plant and equipment is capitalized. The capitalization of interest expense as part of the cost of a qualifying asset commences when expenditures for the asset have been made, activities that are necessary to get the asset ready for its intended use are in progress and interest cost is being incurred. The capitalization period ends when the asset is substantially complete and ready for its intended use.

Depreciation of property, plant and equipment attributable to the processing of donated umbilical cord blood for future transplantation is capitalized as part of inventories, and is expensed to direct costs upon shipment of the donated cord blood units.

(i) Intangible assets

Intangible assets represent the operating rights to operate cord blood bank and are stated at the estimated fair value on the date of acquisition less accumulated amortization. Where payment for an operating right is non-deductible for tax purpose, the simultaneous equations method is used to record the assigned value of the asset and the related deferred tax liability, such that the carrying amount of the asset upon initial recognition less deferred tax liability recognized equals the amount paid for the asset. Amortization expenses are recognized on a straight-line basis over the estimated useful life of the operating rights of 30 years.

Given the environment in which the Group currently operates, it is reasonably possible that the estimated economic useful life of the assets or the Group’s estimate that it will recover its carrying amount from future operations could change in the future.

(j) Impairment of long-lived assets

Long-lived assets, including property, plant and equipment and intangible assets with finite useful lives, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of long-lived assets to be held and used is measured by a comparison of the carrying amount of an asset or asset group to the estimated undiscounted future cash flows expected to be generated by the asset or asset group. If the carrying amount of the long-lived asset or asset group is not recoverable on an undiscounted cash flow basis, an impairment is recognized to the extent that the carrying amount exceeds its fair value. Fair value is determined through various valuation techniques including discounted cash flows models, quoted market values and third-party independent appraisals, as considered necessary. No impairment of long-lived assets was recognized for the years ended March 31, 2012, 2013 and 2014.

(k) Revenue recognition

The Group receives fees for collecting, testing, freezing and storing of cord blood units. Once the cord blood units are collected, tested, screened and successfully meet all of the required attributes, the Group freezes the units and stores them in a cryogenic freezer. Under the cord blood processing and storage agreement (“Agreement”) signed with the customer, the Group charges separate processing fee and storage fees to the customer and such Agreement typically provides for a storage period of eighteen years represented by successive one-year renewal periods. The Group also arranges an insurance policy for customers. The amount of gross storage fees include insurance premiums collected on behalf of a third-party insurance company. The amount attributable to the insurance premiums is included in current and non-current other payables and is not recognized as revenue. The Group has no performance obligation to the customer with respect to the insurance policy.

The Agreement is a multiple-element arrangement, which includes (i) the processing of cord blood unit and (ii) the storage of cord blood unit. The Group accounts for the arrangement under the ASC 605-25, Revenue Recognition — Multiple-Element Arrangements. In accordance with ASC 605-25, revenue arrangements that include multiple elements are analyzed to determine whether the deliverables can be divided into separate units of accounting or treated as a single unit of accounting. The consideration received is allocated among the separate units of accounting based on their relative selling prices determined based on prices of these elements as sold on a stand-alone basis, and the applicable revenue recognition criteria are applied to each of the separate units. In an arrangement with multiple deliverables, the delivered product or service shall be considered a separate unit of accounting when the following criteria are met: (1) the delivered item or items have value to the customer on a standalone basis; and (2) if the arrangement includes a general right of return relative to the delivered item, delivery or performance of the undelivered item or items is considered probable and substantially in the control of the Group. Based on evaluation of the criteria, the Group has determined that the cord blood processing services and storage services are to be accounted for as separate units.

Pursuant to the Agreement, no penalty is charged to customers for early termination of the storage service.

The Group considers all reasonably available information to allocate the overall arrangement fee to processing and storage services based on their relative selling prices.

The Group recognizes processing fee revenue upon successful completion of processing services and when the cord blood unit meets all the required attributes for storage, and recognizes the storage fee revenues ratably over the annual storage period.

During the three years ended March 31, 2012, 2013 and 2014, the Group offered its customers three payment options:

(i) Payment of the processing fee upon delivery of the cord blood unit to the Group’s premises for processing and the annual storage fee in advance at the beginning of each one-year renewal period;

(ii) Payment of the processing fee upon delivery of the cord blood unit to the Group’s premises for processing and prepayment of storage fees for multiple periods; and

(iii) Payment of the processing fee by installment over multiple periods and the annual storage fee in advance at the beginning of each one-year renewal period or prepayment of storage fees for multiple periods by installment. Certain installment option includes an initial processing fee payment upon delivery of the cord blood unit to the Group’s premises for processing and an incremental annual payment for the consecutive periods, representing a surcharge to the total amount of processing fees payable under payment options (i) and (ii).

Under payment option (iii), installments due for payment beyond one year are classified as non-current accounts receivable. The surcharge payable by customers under the installment plan is recognized as interest income using the effective interest method.

The recognition of storage revenue is ceased when the collectability of the storage fees from the customers is not reasonably assured due to delinquency of payment by the customers. During the years ended March 31, 2012, 2013 and 2014, the Group ceased recognizing storage revenue from subscribers who were delinquent for more than 24 months.

According to the notice jointly issued by the Ministry of Finance and the State Administration of Taxation in November 2011, the taxable service revenue provided by the Group’s three main PRC subsidiaries is subject to Value-Added Tax (“VAT”). Beijing Jiachenhong, Guangzhou Nuoya and Zhejiang Lukou are subject to VAT effective for periods starting from September 1, 2012, November 1, 2012, and December 1, 2012, respectively. VAT at a general rate of 6% on the invoiced amount is collected on behalf of tax authorities in respect of the services rendered. Prior to those periods, the Group’s three main PRC subsidiaries were subject to business tax at a general rate of 5% of service revenues. Revenue is stated net of VAT or business tax.

(l) Research and development costs

Research and development costs are incurred for research activities conducted to enhance operating efficiencies, collection and storage technologies, and measures to improve the results in umbilical cord blood stem cells extraction and separation. They also include research expenses on the use of cord blood stem cells in different medical treatments. Research and development costs are expensed as incurred.

(m) Advertising and promotion costs

Advertising and promotion costs are expensed as incurred. Advertising and promotion costs included in sales and marketing expenses in the consolidated statements of comprehensive income amounted to RMB12,460, RMB19,215 and RMB30,785 (US$4,952) for the years ended March 31, 2012, 2013 and 2014, respectively.

(n) Retirement and other postretirement benefits

Contributions to retirement schemes (which are defined contribution plans) are charged to the consolidated statements of comprehensive income when the related employee service is provided. The Group does not have any defined benefit retirement plans.

(o) Debt issuance costs

Costs incurred by the Company that are directly attributable to the issuance of the convertible notes are deferred and charged to the consolidated statements of comprehensive income using an effective interest rate method from the date the convertible notes were issued to the earliest date the holders of the convertible notes can demand payment, which is five years.

(p) Income taxes

Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statements carrying amounts of existing assets and liabilities and their respective tax bases and tax loss and tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. A valuation allowance is provided to reduce the amount of deferred tax assets if it is considered more likely than not that some portion or all of the deferred tax assets will not be realized. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the consolidated statements of comprehensive income in the period that includes the enactment date.

The Group recognizes in the consolidated financial statements the impact of a tax position if that position is more likely than not of being sustained upon examination, based on the technical merits of the position. Recognized income tax positions are measured at the largest amount that is greater than 50% likely of being realized. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs. The Group has elected to classify interest and penalties related to unrecognized tax benefits, if and when required, as part of income tax expense in the consolidated statements of comprehensive income.

A deferred tax liability is not recognized for the excess of the Company’s financial statements carrying amount over the tax base of its investment in a foreign subsidiary, if the subsidiary has invested or will invest the undistributed earnings indefinitely.

(q) Commitments and contingencies

In the normal course of business, the Group is subject to contingencies, including legal proceedings and claims that relate to a wide range of matters, including, among others, product liability. The Group records accruals for such contingencies based upon the assessment of the probability of occurrence and, where determinable, an estimate of the liability. The Group may consider many factors in making these assessments including past history and the specifics of each matter.

(r) Earnings per share

Basic earnings per ordinary share is computed by dividing net income attributable to ordinary shareholders by the weighted average number of ordinary shares outstanding during the year using the two-class method. Under the two-class method, net income attributable to common shareholders is allocated between ordinary share and participating securities based on contractual participating rights of security to share in undistributed earnings as if all of the earnings had been distributed.

Diluted earnings per share is computed by dividing net income attributable to ordinary shareholders, as adjusted to exclude any income or expenses related to dilutive ordinary equivalents shares by the weighted average number of ordinary shares and dilutive potential ordinary shares outstanding during the period. Dilutive potential ordinary shares consist of the ordinary shares issuable upon the exercise of outstanding share options by applying the treasury stock method and the ordinary shares issuable upon the conversion of the convertible notes applying the if-converted method. Dilutive potential ordinary shares in the diluted earnings per share computation are excluded to the extent that their effect is anti-dilutive.

(s) Share option plan

The Group recognizes share-based payments as compensation cost and measures such cost based on the grant date fair value of the award using the Black-Scholes option-pricing model. Compensation expense is recognized on a straight-line basis over the requisite service period, which is generally the same as the vesting period.

The service inception date is the date at which the requisite service period begins. The service inception date usually is the grant date; however the service inception date precedes the grant date if (a) an award is authorized, (b) service begins before a mutual understanding of the key terms and conditions of a share-based payment award is reached, and (c) either of the following conditions applies: (1) the award’s terms do not include a substantive future requisite service condition that exists at the grant date or (2) the award contains a market or performance condition that if not satisfied during the service period preceding the grant date and following the inception of the arrangement results in forfeiture of the award. For the purpose of determining the service inception date, authorization of an award is the date on which all approval requirements are completed unless approval is perfunctory.

(t) Segment reporting

The Group has one operating segment, as defined by ASC 280 Segment Reporting, which is processing and storage of cord blood units. All of the Group’s operations and customers are located in the PRC. Consequently, no geographic information is presented.

(u) Fair value measurement

The Group utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible. The Group determines fair value based on assumptions that market participants would use in pricing an asset or liability in the principal or most advantageous market. When considering market participant assumptions in fair value measurements, the following fair value hierarchy distinguishes between observable and unobservable inputs, which are categorized in one of the following levels:

· Level 1 Inputs: Unadjusted quoted prices in active markets for identical assets or liabilities accessible to the reporting entity at the measurement date.

· Level 2 Inputs: Other than quoted prices included in Level 1 inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the asset or liability.

· Level 3 Inputs: Unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset or liability at measurement date.

The Group did not have any non-financial assets or liabilities that are measured at fair value on a recurring basis as of March 31, 2012, 2013 and 2014.

See Note 22 to the consolidated financial statements.

(v) Recently issued accounting standards

In March 2013, the Financial Accounting Standard Board (“FASB”) issued ASU 2013-05, Foreign Currency Matters (Topic 830): Parent’s Accounting for the Cumulative Translation Adjustment upon Derecognition of Certain Subsidiaries or Groups of Assets within a Foreign Entity or of an Investment in a Foreign Entity (“ASU 2013-05”), which defines the treatment of the release of cumulative translation adjustments upon derecognition of certain subsidiaries or groups of assets within a foreign entity or of an investment in a foreign entity. ASU 2013-05 is effective for fiscal years, and interim periods within those years, beginning after December 15, 2013. Early adoption is permitted and prior periods should not be adjusted. The Company adopted the new guidance on April 1, 2014. The adoption of this guidance did not have a material impact on the consolidated financial statements.

In July 2013, the FASB issued ASU 2013-11,Income Taxes (Topic 740): Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carry forward, a Similar Tax Loss, or a Tax Credit Carry forward Exists (“ASU 2013-11”). ASU 2013-11 requires an entity to present an unrecognized tax benefit as a reduction of a deferred tax asset for a net operating loss (“NOL”) carry forward, or similar tax loss or tax credit carry forward, rather than as a liability when the uncertain tax position would reduce the NOL or other carry forward under the tax law of the applicable jurisdiction and the entity intends to use the deferred tax asset for that purpose. ASU 2013-11 is effective prospectively for fiscal years, and interim periods within those years, beginning after December 15, 2013. The Company adopted the new guidance on April 1, 2014. The adoption of this guidance did not have a material impact on the consolidated financial statements.

In April 2014, the FASB issued ASU 2014-08, Presentation of Financial Statements (Topic 205) and Property, Plant, and Equipment (Topic 360): Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity (“ASU 2014-08”), which required that only disposals representing a strategic shift in operations should be presented as discontinued operations. ASU 2014-08 is effective for disposals or classification as held for sale that occur within annual periods beginning on or after December 15, 2014 and interim period thereafter for public business entities.

In May 2014, the FASB and the International Accounting Standard Board jointly issued a converged standard on the revenue recognition from contacts with customers. The new standard will be introduced into the FASB’s ASC Topic 606 by ASU 2014-09,Revenue from Contacts with Customers (“ASU 2014-09”). The core principle of the new standard is for companies to recognize revenue to depict the transfer of goods or services to customers in amounts that reflect the consideration to which the Company expects to be entitled in exchange for those goods or services. ASU 2014-09 is effective for annual and interim periods beginning after December 15, 2016 for public business entities applying U.S. GAAP. The Company is in the process of evaluating the impact on the consolidated financial statements.

- Definition

The entire disclosure for all significant accounting policies of the reporting entity.

+ References+ Details

Accounts receivable, net

12 Months Ended

Mar. 31, 2014

Accounts receivable, net

Accounts receivable, net

3 Accounts receivable, net

(a) Accounts receivable consist of the following:

	March 31,
	2013		2014		2014
	RMB		RMB		US$

Accounts receivable	372,919		383,794		61,739
Less: Allowance for doubtful accounts	(50,473	)	(63,025	)	(10,138	)
Total accounts receivable, net	322,446		320,769		51,601

Representing:

Current portion:
- processing fees	49,092		64,838		10,430
- storage fees	23,357		28,894		4,648
- others	627		1,541		248
	73,076		95,273		15,326
Non-current portion:
- processing fees	249,370		225,496		36,275
Total accounts receivable, net	322,446		320,769		51,601

Non-current gross accounts receivable as of March 31, 2014 are due for payment as follows:

	March 31, 2014
	RMB	US$
Fiscal years ending March 31,
2016	35,442	5,701
2017	32,161	5,174
2018	28,363	4,563
2019	25,537	4,108
2020 and thereafter	146,696	23,598
	268,199	43,144

(b) An analysis of the allowance for doubtful accounts is as follows:

	Year ended March 31,
	2012	2013		2014		2014
	RMB	RMB		RMB		US$

Balance at beginning of year	39,956	52,544		50,473		8,119
Charged to allowance for doubtful accounts	12,588	7,468		17,973		2,891
Write-off charged against the allowance for the year		(9,539	)	(5,421	)	(872	)
Balance at end of year	52,544	50,473		63,025		10,138

The Group continuously monitors the recoverability of the accounts receivable, the credit quality of such receivables, the effectiveness and the efficiency of its collection efforts.

During the years ended March 31, 2013 and 2014, the Group wrote-off accounts receivable of RMB9,539 and RMB5,421 (US$872), which were aged over three years since there was sufficient evidence available to prove the debtor’s inability to make payments.

- Definition

The entire disclosure for claims held for amounts due a entity, excluding financing receivables. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Includes disclosure for allowance for credit losses.

+ References+ Details

Inventories

12 Months Ended

Mar. 31, 2014

Inventories

Inventories

4 Inventories

Inventories consist of the following:

	March 31,
	2013	2014	2014
	RMB	RMB	US$

Current portion:
- consumables and supplies	10,265	31,583	5,080

Non-current portion:
- processing costs capitalized in donated umbilical cord blood	39,730	48,385	7,783
Total current and non-current inventories	49,995	79,968	12,863

Collection, testing and processing costs attributable to the processing of donated umbilical cord blood are capitalized as inventories. Management assesses the recoverability of such inventories with reference to future projections of matching fees, number of donated cord blood units of the Group, demand for cord blood units for transplantation and research purposes, and the probability of finding a match in light of the number of units held. Based on such assessments, the management considers that the cord blood processing costs capitalized are recoverable and no provision for inventories was made as of March 31, 2012, 2013 and 2014.

The Group recognizes the revenue for one matched donated umbilical cord blood unit upon shipment of the unit and recognizes the direct costs equal to the carrying amount of the total inventory (donated umbilical cord blood units) divided by the estimated future number of successful matches which would become realized through sales during the estimated weighted average remaining useful life of the donated umbilical cord blood unit. As of March 31, 2014, the weighted average remaining useful life of the donated umbilical cord blood units was estimated to be approximately 19 years. Based on the historical increase in the number of donated umbilical cord blood matching inquiries and the number of successful matches of donated umbilical cord blood units, the Group estimated the number of successful matches of donated umbilical cord blood units will increase by 7% per annum. There were no material changes to the estimates and assumptions underlying the methodology for the three years ended March 31, 2012, 2013 and 2014.

- Definition

The entire disclosure for inventory. This may include, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the major classes of inventory, and the nature of the cost elements included in inventory. If inventory is stated above cost, accrued net losses on firm purchase commitments for inventory and losses resulting from valuing inventory at the lower-of-cost-or-market may also be included. For LIFO inventory, may disclose the amount and basis for determining the excess of replacement or current cost over stated LIFO value and the effects of a LIFO quantities liquidation that impacts net income.

+ References+ Details

Prepaid expenses and other receivables

12 Months Ended

Mar. 31, 2014

Prepaid expenses and other receivables

Prepaid expenses and other receivables

5 Prepaid expenses and other receivables

Prepaid expenses and other receivables consist of the following:

	March 31,
	2013	2014	2014
	RMB	RMB	US$

Prepaid expenses	9,372	20,593	3,313
Tax receivables	—	13,406	2,157
Other receivables	2,230	3,011	484
Total prepaid expenses and other receivables	11,602	37,010	5,954

Other receivables mainly include advance payments to employees and rental deposits.

Property, plant and equipment, net

12 Months Ended

Mar. 31, 2014

Property, plant and equipment, net

Property, plant and equipment, net

6 Property, plant and equipment, net

Property, plant and equipment, net consist of the following:

	March 31,
	2013		2014		2014
	RMB		RMB		US$

Buildings	187,529		578,513		93,064
Leasehold improvements	44,264		14,864		2,391
Machineries	105,899		118,449		19,054
Motor vehicles	11,087		14,885		2,394
Furniture, fixtures and office equipment	27,588		35,433		5,700
Construction-in-progress	205,657		9,684		1,558
	582,024		771,828		124,161
Less: Accumulated depreciation	(113,752	)	(145,196	)	(23,357	)
Total property, plant and equipment, net	468,272		626,632		100,804

Pursuant to the final purchase contract dated June 28, 2012, the total purchase price of the property, land use right, related taxes, and other expenditures associated with the assets to be used by Guangzhou Nuoya was RMB107,294. The Group paid the full amount as of March 31, 2013.

In November 2012, the Group signed a contract with a third party for further development and renovation of the newly purchased property in the Guangdong province. A total of RMB105,954 (US$17,044) has been paid as of March 31, 2014, and RMB2,800 (US$450) was included in accrued expenses and other payables in accordance to the construction completion report. The construction has been completed as of March 31, 2014.

In January 2013, the Group signed a purchase contract with a third party for the purchase of buildings and associated land use right in the Zhejiang province. The Group paid the full purchase contract amount and relevant taxes of RMB87,508 as of March 31, 2013.

In 2013, the Group signed contracts with two third parties for the subsequent development and renovation of the newly purchased property in the Zhejiang province. RMB52,474 (US$8,441) was paid and RMB12,000 (US$1,930) was included in accrued expense and other payables as of March 31, 2014 in accordance to the construction completion report. The construction has been completed as of March 31, 2014. The Group is still in the process of obtaining the ownership certificate of the building in the Zhejiang province.

Depreciation expense of property, plant and equipment is allocated to the following expense items:

	Year ended March 31,
	2012	2013	2014	2014
	RMB	RMB	RMB	US$

Direct costs	13,481	17,421	18,150	2,920
Research and development	3,212	2,073	1,863	300
Sales and marketing	1,803	2,805	2,611	419
General and administrative	6,240	8,954	9,820	1,580
Total depreciation expense	24,736	31,253	32,444	5,219

Interest cost incurred consists of the following:

	Year ended March 31,
	2012	2013	2014	2014
	RMB	RMB	RMB	US$

Interest cost capitalized	—	1,274	25,912	4,168
Interest cost charged to income	3,287	70,097	70,075	11,273
Total interest cost incurred	3,287	71,371	95,987	15,441

As of March 31, 2013 and 2014, buildings with carrying value of RMB121,603 and RMB114,570 (US$18,430) were collateralized to banks for short-term bank loans of RMB50,000 and RMB60,000 (US$9,652), respectively (Note 11).

- Definition

The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.

+ References+ Details

Non-current prepayments

12 Months Ended

Mar. 31, 2014

Non-current prepayments

Non-current prepayments

7 Non-current prepayments

Non-current prepayments consist of the following:

		March 31,
	Note	2013	2014	2014
		RMB	RMB	US$

Investment deposit	(i)	212,188	208,591	33,555
Deposit for machineries purchase		445	303	49
Total non-current prepayments		212,633	208,894	33,604

Note:

(i) During the year ended March 31, 2013, the Group signed a Letter of Intent with a third party for a potential investment in a company in the healthcare industry and the Group remitted a refundable earnest money of US$33,660 (RMB208,591) to this third party and commenced the relevant work with respect to the investment opportunity. As of the date of this report, the project is still on-going.

Intangible assets, net

12 Months Ended

Mar. 31, 2014

Intangible assets, net

Intangible assets, net

8 Intangible assets, net

	March 31,
	2013		2014		2014
	RMB		RMB		US$

Cord blood bank operating rights	138,628		138,628		22,300
Less: Accumulated amortization	(13,458	)	(18,079	)	(2,908	)
Total intangible assets, net	125,170		120,549		19,392

Intangible assets represent the cord blood bank operating rights in the Guangdong province and the Zhejiang province, the PRC.

The cord blood bank operating right in the Guangdong province was acquired through the acquisition of Guangzhou Nuoya in May 2007. The estimated useful life of the operating right is thirty years. Amortization expenses of the operating right in the Guangdong province were RMB971, RMB971 and RMB971 (US$156) for the years ended March 31, 2012, 2013 and 2014, respectively. The operating right is subject to renewal and the next renewal is due in May 2015.

In February 2011, the Group acquired the right to operate the cord blood bank in the Zhejiang province from a third party for cash consideration of US$12.5 million (equivalent to RMB82,124) which was fully settled in August 2011. Payment for the operating right is non-deductible for tax purpose. The simultaneous equations method is used to record the assigned value of the asset of RMB109,499 and a related deferred tax liability of RMB27,375 (Note 17(c)), in accordance with the guidance in ASC 740-10-25-51, such that the carrying amount of the asset upon initial recognition less the related deferred tax liability equals the cash consideration paid. The estimated useful life of the Zhejiang operating right is thirty years. Amortization expenses were RMB3,650, RMB3,650 and RMB3,650 (US$587) for the years ended March 31, 2012, 2013 and 2014, respectively. The operating right is subject to renewal and the next renewal is due in September 2016.

The Group determined that a thirty-year period to amortize the cord blood bank operating rights was appropriate, following the pattern in which the expected benefits of the acquired asset will be consumed or otherwise used up. The Group’s renewal period with the provincial governmental authorities generally is for a period of three years. The Group has historically renewed cord blood bank operating rights without incurring any significant costs. There are no other legal or regulatory provisions that limit the useful life of the cord blood bank operating rights or that cause the cash flows and useful life of such cord blood bank operating right to be constrained. In addition, the Group expects the effect of obsolescence, demand, competition, and other economic factors to be minimal.

The Group engaged independent third party valuation firms in determining the fair values of the cord blood bank operating rights during the acquisitions. The fair values of the cord blood bank operating rights were determined using an income approach and considered assumptions (including turnover rate) that a market participant would make consistent with the highest and best use of the asset by market participants. The periods of expected cash flows used to measure the fair values of the cord blood bank operating rights were thirty years. Without evidence to the contrary, the Group expects that the cord blood bank operating rights will be renewed at the same rate as a market participant would expect, and no other factors would indicate a different useful life is more appropriate. Accordingly, in the absence of other entity-specific factors, the useful life of the cord blood bank operating rights was determined to be thirty years.

A straight-line method of amortization has been adopted as the pattern in which the economic benefits of the operating rights are used up cannot be reliably determined. Estimated amortization expenses for the years afterwards are:

	March 31, 2014
	RMB	US$
Fiscal years ending March 31,
2015	4,621	743
2016	4,621	743
2017	4,621	743
2018	4,621	743
2019 and thereafter	102,065	16,420
Total amortization expenses	120,549	19,392

Available-for-sale equity securities

12 Months Ended

Mar. 31, 2014

Available-for-sale equity securities

Available-for-sale equity securities

9 Available-for-sale equity securities

	March 31,
	2013	2014	2014
	RMB	RMB	US$

Life Corporation Limited - listed on Australian Securities Exchange	8,284	4,630	745
Cordlife Group Limited - listed on Singapore Exchange	80,120	139,617	22,459
Total listed equity securities, at market	88,404	144,247	23,204

During the year ended March 31, 2008, the Group acquired 11,730,000 ordinary shares of Cordlife Limited (“CBB”) at a total cost of RMB53,699. CBB was a provider of cord blood banking services with operations in Singapore, Hong Kong, India, Indonesia and the Philippines, and is listed on the Australian Securities Exchange.

During the year ended March 31, 2009, the Group acquired an additional 5,795,000 ordinary shares of CBB at a total cost of RMB11,172, satisfied in cash. The acquisition of additional ordinary shares led to an increase in the Group’s equity interest in CBB from 12.9% as of March 31, 2008 to 18.9% as of March 31, 2009. The Group’s equity interest in CBB was diluted to 16.3% as of March 31, 2010 due to the issuance of additional shares by CBB during the year ended March 31, 2010.

During the year ended March 31, 2011, the Company subscribed for 6,841,666 shares of CBB at a total cost of RMB13,245, satisfied in cash. As a result, the Group held 24,366,666 ordinary shares of CBB, representing a 16.8% equity interest as of March 31, 2011. The Group’s equity interest in CBB was diluted to 16.1% as a result of the exercise of employees’ share options of CBB during the period from March 31, 2011 to the time when the capital reduction occurred on June 30, 2011.

On June 16, 2011, the shareholders of CBB approved a capital reduction by way of distribution in specie. The scheme involved a spin off of Cordlife Pte Ltd from CBB, and the shares of Cordlife Pte Ltd were distributed to the then shareholders of CBB on a pro rata basis. The restructuring and distribution in specie were completed and effective on June 30, 2011. After the restructuring of CBB as of June 30, 2011, the Group owned a total of 24,366,666 shares, representing a 16.1% equity interest in each of CBB and Cordlife Pte Ltd, respectively. The Group’s investments in CBB upon the completion of restructuring were recognized as two separate investments consisting of CBB and Cordlife Pte Ltd. The capital reduction or the distribution in specie by CBB did not constitute a sale of available-for-sale equity securities. The cost of both investments was based on their respective estimated fair values as of the restructuring date and adjusted by the unrealized holding gains of CBB recorded in accumulated other comprehensive income on pro rata basis. After the restructuring, Cordlife Pte Ltd was a private company, whose shares did not have a readily determinable fair value. The investment in Cordlife Pte Ltd was therefore accounted for by the cost method under ASC 325-20, before its listing on the Singapore Exchange on March 29, 2012.

In connection with a proposed listing on the Singapore Exchange, Cordlife Pte Ltd changed its name to CGL. On March 29, 2012, CGL was listed on the Singapore Exchange. Upon the listing of CGL, the Group’s equity interests in both CGL and CBB were diluted to 10.5% and 14.1% respectively as a result of new shares issued in the public offering of CGL and the exercise of options issued by CBB to other third parties. Upon CGL’s listing on March 29, 2012, the Group accounted for its investment in CGL at fair value.

As of March 31, 2013, the Group held 24,366,666 ordinary shares in both CBB and CGL, representing a 14.1% and 10.5% equity interest in CBB and CGL, respectively.

In July 2013, CBB changed its name to Life Corporation Limited (“LFC”). In December 2013, LFC did a reverse stock split at the rate of 1 to 3.

As of March 31, 2014, the Company held 8,122,222 ordinary shares in LFC and 24,366,666 ordinary shares in CGL. The Group’s equity interest in LFC and CGL was 11.4% and 9.2% respectively as of March 31, 2014.

In February and August 2013 respectively, CGL announced dividends of SGD0.01 per ordinary share relating to CGL’s fiscal year ended June 30, 2013. As a result, the Group received dividend of SGD487 (equivalent to RMB2,414) which was recognized in dividend income in the consolidated statement of comprehensive income.

As of March 31, 2013, the cost basis of the available-for-sale equity securities was RMB40,690. Total unrealized net holding losses of LFC was RMB3,024 and total unrealized net holding gains of CGL was RMB59,836. The aggregate fair values was RMB88,404 as of March 31, 2013.

As of March 31, 2014, the cost basis of the available-for-sale equity securities was RMB40,690 (US$6,546). Total unrealized net holding losses of LFC was RMB6,527 (US$1,050) and total unrealized net holding gains of CGL was RMB121,047 (US$19,472). The aggregate fair values was RMB144,247 (US$23,204) as of March 31, 2014.

The available-for-sale equity securities are held by a subsidiary whose functional currency is Hong Kong dollars. Both securities are traded in a foreign market. The fair values are based on the current market values of the securities and the current exchange rates between Hong Kong dollars and Australia dollars or Singapore dollars, as applicable. Both investments are translated into RMB, the Group’s reporting currency, using the exchange rate at the balance sheet dates.

The Group determined that the decline in market value of LFC for the years ended March 31, 2013 and 2014 was temporary and therefore no impairment loss was recognized. As of March 31, 2013 and 2014, accumulated other-than-temporary impairment was RMB37,426, which was recorded in earnings in December 2008.

- Definition

The entire disclosure for investments in certain debt and equity securities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=27724398&loc=d3e27290-111563

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 50

-Paragraph 9

-URI http://asc.fasb.org/extlink&oid=27724398&loc=d3e27357-111563

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-Glossary Debt Security

-URI http://asc.fasb.org/extlink&oid=6509901

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 30

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6379141&loc=d3e15032-111544

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=27724398&loc=d3e27232-111563

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 320

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6957658&loc=d3e62557-112803

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=27724398&loc=d3e27161-111563

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 50

-Paragraph 10

-URI http://asc.fasb.org/extlink&oid=27724398&loc=d3e27405-111563

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-Glossary Equity Security

-URI http://asc.fasb.org/extlink&oid=6511694

+ Details

Other investment

12 Months Ended

Mar. 31, 2014

Other investment

Other investment

10 Other investment

	March 31,
	2013	2014	2014
	RMB	RMB	US$

Unlisted equity securities, at cost	189,129	189,129	30,424

In May 2010, the Group completed its acquisition of 19.92% equity interest of Shandong Province Qilu Stem Cells Engineering Co., Ltd. (“Qilu Stem Cells”), which operates a cord blood bank in the Shandong province, the PRC. The Group does not have significant influence over the financial and operating decisions of Qilu Stem Cells. The investment is stated at cost as the equity securities do not have a readily determinable fair value.

In February 2013, the Group completed its acquisition of 4.08% equity interest of Qilu Stem Cells from Cordlife Service (S) Pte. Ltd., a wholly owned subsidiary of CBB at the time of the acquisition, satisfied in cash of US$8.65 million (RMB54,766). Upon completion of the transaction, the Group’s effective equity interest in Qilu Stem Cells increased from 19.92% to 24%. Although the Group increased its effective equity interest in Qilu Stem Cells to over 20%, the Group does not have any representation in the board of directors and does not have significant influence in Qilu Stem Cells. Accordingly, the investment in Qilu Stem Cells is accounted under the cost method as of March 31, 2013 and 2014.

Dividends declared and paid by Qilu Stem Cells during the years ended March 31, 2012, 2013 and 2014 of RMB7,217, nil and RMB7,497 (US$1,206), respectively, were recognized in dividend income in the consolidated statement of comprehensive income.

Bank loan	12 Months Ended
Bank loan	Mar. 31, 2014
Bank loan
Bank loan	11 Bank loan On July 11, 2012, the Group borrowed RMB50,000 from Hangzhou Bank, a commercial bank in the PRC. The term of the loan is one year. The loan bears a floating interest rate equaling to 120% of the base lending rate quoted by the People’s Bank of China, which is adjusted on the 20th day of the third month of each quarter. As of March 31, 2013, the bank loan bears interest at 7.2% per annum. The Group repaid the bank loan in full on July 10, 2013. On August 12, 2013, the Group borrowed RMB60,000 (US$9,652) from Hangzhou Bank for one year. The loan bears a monthly fixed interest rate at 0.6%.

- Definition

The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.

+ References+ Details

Accrued expenses and other payables

12 Months Ended

Mar. 31, 2014

Accrued expenses and other payables

Accrued expenses and other payables

12 Accrued expenses and other payables

Accrued expenses and other payables consist of the following:

		March 31,
	Note	2013	2014	2014
		RMB	RMB	US$

Insurance premiums received on behalf of an insurance company	(i)	12,411	15,292	2,460
Other taxes payables		1,616	3,927	632
Accrued salaries, bonus and welfare expenses		17,828	23,005	3,701
Accrued consultancy and professional fees		7,770	3,599	579
Payable for convertible notes interests	(ii)	26,639	26,188	4,213
Payable for debt issuance costs		3,242	—	—
Payable for property, plant and equipment	(iii)	—	15,969	2,569
Other payables	(iv)	14,500	14,579	2,344
Total accrued expenses and other payables		84,006	102,559	16,498

Notes:

(i) The Group has an agreement with an insurance company under which the Group is granted the authority to collect insurance premiums on behalf of the insurance company from customers who store umbilical cord blood in the Group’s cord blood bank and are enrolled in the insurance scheme offered by the insurance company. The insurance premiums amount collected and payable over one year are recorded in other non-current liabilities in the consolidated balance sheets.

(ii) The payable for convertible notes interests represents the interest accrued based on coupon interest rate of 7% of outstanding principle of convertible notes, which is to be settled annually on April 27 (Note 14).

(iii) Payable for property, plant and equipment related to the amount payable for the development and renovation of the newly purchased properties (Note 6).

(iv) Other payables mainly include fee refundable to customers whose cord blood unit does not qualify for subsequent storage and other operating procurement payables.

Deferred revenue

12 Months Ended

Mar. 31, 2014

Deferred revenue

Deferred revenue

13 Deferred revenue

(a) Deferred revenue consists of the following:

	March 31,
	2013	2014	2014
	RMB	RMB	US$

Prepayments by customers prior to completion of cord blood processing services	94,471	93,597	15,056
Unearned storage fees	608,115	926,756	149,083
Total current and non-current deferred revenue	702,586	1,020,353	164,139

Representing:
Current portion	172,328	196,432	31,599
Non-current portion	530,258	823,921	132,540
Total current and non-current deferred revenue	702,586	1,020,353	164,139

(b) An analysis of the unearned storage fees is as follows:

	Year ended March 31,
	2012		2013		2014		2014
	RMB		RMB		RMB		US$

Balance at beginning of year	199,470		361,034		608,115		97,824
Deferred revenue arising from new customers	260,531		376,536		485,290		78,067
Credited to income	(98,967	)	(129,455	)	(166,649	)	(26,808	)
Balance at end of year	361,034		608,115		926,756		149,083

Convertible notes

12 Months Ended

Mar. 31, 2014

Convertible notes

Convertible notes

14 Convertible notes

On April 27, 2012, the Company completed the sale of US$65 million in aggregate principal amount of 7% coupon interest rate senior unsecured convertible notes to KKR China Healthcare Investment Limited (“KKRCHIL”) (the “KKR Notes”). The KKR Notes are convertible into the Company’s ordinary shares at a conversion price of US$2.838 per share. The Company received gross proceeds of US$65 million and incurred debt issuance costs of RMB14,260 from the issuance of the KKR Notes. The KKR Notes are senior unsecured obligations, maturing on April 27, 2017 and are not redeemable prior to their maturity at the Company’s option. The KKR Notes are convertible at any time in whole or in part, into the Company’s ordinary shares at the conversion price, subject to customary anti-dilution adjustments for significant corporate events. On the maturity date, the Company is obligated to pay a redemption amount on the unconverted portion of the KKR Notes that is calculated to provide a 12% Internal Rate of Return (“IRR”).

On October 3, 2012, the Company completed the sale of aggregate US$50 million senior unsecured convertible notes to Golden Meditech Holdings Limited (“GMHL”), which is a major shareholder of the Company (the “GM Notes”). The GM Notes carry a 7% coupon interest rate and are convertible into the Company’s ordinary shares at a conversion price of US$2.838 per share. The Company received gross proceeds of US$50 million and incurred debt issuance costs of RMB4,258 from the issuance of the GM Notes. The GM Notes are senior unsecured obligations, maturing on October 3, 2017 and are not redeemable prior to their maturity at the Company’s option. The GM Notes are convertible at any time in whole or part, into the Company’s ordinary shares at the conversion price, subject to customary anti-dilution adjustments for significant corporate events. On the maturity date, the Company is obligated to pay a redemption amount on the unconverted portion of the GM Notes that is calculated to provide a 12% IRR.

The carrying amounts of the KKR Notes and GM Notes (collectively the “Notes”) as of March 31, 2013 and 2014 are summarized in the following table:

	March 31,
	2013	2014	2014
	RMB	RMB	US$

Principal amount of the KKR Notes	409,764	403,315	64,879
Principal amount of the GM Notes	315,226	310,302	49,917
Cumulative interest payables	26,791	64,136	10,317
Carrying amount	751,781	777,753	125,113

The Notes holders have the right to require the Company to redeem all or any portion of the Notes upon occurrence of events of default. Such events of default under the Notes include suspension from trading or failure of the Company’s ordinary shares to be listed over certain periods (subject to certain exceptions), failure to deliver ordinary shares upon conversion, or failure to pay principal or interest to the holder within certain periods when due and payable (including, without limitation, the Company’s failure to pay any redemption payments), bankruptcy, materially breaches of any covenants or terms in the Notes, the incurrence of any indebtedness of the Group and any final judgment or judgment against the Group exceeding certain amount, and any other event or events that could be expected to have material adverse effects on the Group. From and after the thirtieth day following the occurrence, and during the continuance, of an event of default under the Notes, the interest rate shall be increased to twenty-two and one-half percent (22.5%) per annum.

The Notes are entitled to a special redemption payment in the event the Group breaches certain covenants. The KKR Note are also entitled to a special redemption payment in the event GMHL or certain members of the Company’s senior management violate the terms of certain lock-up agreements they have entered into in favor of KKRCHIL. The Notes contain customary ongoing covenants, including affirmative covenants and negative covenants. Covenants are set out in the convertible notes purchase agreement and the Notes, including but not limited to compliance with Securities and Exchange Commission filings and all applicable laws and rules; maintaining Form F-3 eligibility and maintaining and keeping all the current held cord blood banking licenses effective; the Company shall not, without the prior written consent of the Notes holders, change its principal business; dissolve, liquidate, reorganize or restructure; merge with any other entity; commence any case, proceeding or other action under bankruptcy, insolvency or similar law; acquire or dispose of assets other than in the ordinary course of business; approve any budget or business plan; incur any indebtedness such that the outstanding indebtedness is in excess of US$22 million for KKR Notes and US$87 million for GM Notes respectively. Any amendment or waiver thereof requires the affirmative consent of a majority of the holder of all outstanding Notes. Additionally, additional payments on the Notes shall be made in the event the Group pays any excess cash dividend in any financial year (see Note 19). Such term provides KKRCHIL and GMHL with the ability to participate in any excess cash dividend.

The Company has determined that the conversion feature embedded in the Notes should not be bifurcated and accounted for as a derivative pursuant to ASC 815, Derivatives and Hedging, since the embedded conversion feature is indexed to the Company’s own stock and would have been classified in shareholders’ equity if it were a free-standing derivative instrument. The Company has determined that the embedded put options that can accelerate the repayment of the Notes and contingent interest feature are clearly and closely related to the debt host contract and are not separately accounted for as a derivative pursuant to the ASC 815. Further, since the conversion price of the Notes exceeded the market price of the Company’s ordinary shares on the date of commitment, there was no beneficial conversion feature.

The Company accrued interest on the Notes based on the guaranteed 12% IRR per annum. The difference between the accrued interest rate of 12% and the coupon rate of 7% of the Notes is recorded in convertible notes in the consolidated balance sheets. Debt issuance costs capitalized in connection with the issuance of convertible notes are amortized from the date the Notes were issued to the earliest date the holders of the Notes can demand payment, which is five years.

Interest relating to the Notes was recognized as follows:

	Year ended March 31,
	2013		2014		2014
	RMB		RMB		US$

KKR Notes interest incurred	45,959		50,475		8,120
GM Notes interest incurred	18,761		37,994		6,112
Amortization of debt issuance costs	3,062		3,610		581
Notes related interest cost capitalized	(1,207	)	(24,822	)	(3,993	)
Total interest expense	66,575		67,257		10,820

Shareholders' equity	12 Months Ended
Shareholders' equity	Mar. 31, 2014
Shareholders' equity
Shareholders' equity	15 Shareholders’ equity *(a)* *Share capital* The Company had 75,406,875 shares outstanding as of March 31, 2011. During the year ended March 31, 2012, 2,266,728 ordinary shares were repurchased and cancelled under the share repurchase program (see Note 15(d)) and as a result the Company had 73,140,147 shares outstanding as of March 31, 2012. During the year ended March 31, 2013, 7,450,914 ordinary shares were repurchased under the share repurchase program (see Note 15(d)), and 7,314,015 of them were sold to CGL (see Note 1(b)). The remaining 136,899 ordinary share repurchased had not been cancelled and was presented as treasury stock in the consolidated balance sheets. As a result, the Company had 73,003,248 shares outstanding as of March 31, 2013 and 2014. *(b)* *Statutory reserves* According to PRC rules and regulations and their Articles of Association, Beijing Jiachenhong, Guangzhou Nuoya and Zhejiang Lukou are required to transfer 10% of net income, as determined in accordance with the relevant financial regulations established by the Ministry of Finance of the PRC, to a statutory surplus reserve until the reserve balance reaches 50% of their respective registered capital. The transfer to this reserve must be made before distribution of dividends to equity holders can be made. The statutory surplus reserve is non-distributable but can be used to make good previous years’ losses, if any, and may be converted into issued capital in proportion to the respective equity holding of the equity holders, provided that the balance of the reserve after such conversion is not less than 25% of the registered capital. Transfers of RMB17,656, RMB22,638 and RMB22,858 (US$3,677) have been made to the statutory surplus reserve by Beijing Jiachenhong and Guangzhou Nuoya for the years ended March 31, 2012, 2013 and 2014, respectively. Accumulated statutory surplus reserve as of March 31, 2013 and 2014 amounted to RMB78,079 and RMB100,937 (US$16,237), respectively. Lukou was still in accumulated loss position, and no surplus reserve was made accordingly. *(c)* *Warrants and options* In connection with the Company’s Initial Public Offering in December 2006, the Company issued an option for US$0.1 to EarlyBirdCapital, Inc. (“EBC”) to purchase 500,000 units (“Units”) at an exercise price of US$6.60 per Unit prior to its expiry on December 13, 2011. Each Unit consists of one share of the Company’s common stock and two warrants (“IPO Warrants”). Each holder of an IPO Warrant was entitled to purchase one share of the Company’s common stock at an exercise price of US$5.00 prior to its expiry on December 13, 2010. The option could be exercised for cash or on a cashless basis at the holders’ option, such that the holder could use the appreciated value of the option (the difference between the exercise prices of the option and the underlying warrants and the market price of the Units and underlying securities) to exercise the option without paying cash. However, the Company had no obligation to net cash settle the exercise of the option or the warrants underlying the option. The holder of the option will not be entitled to exercise the option or the warrants underlying the option unless a registration statement covering the securities underlying the option is declared effective or an exemption from registration was available. If the holder was unable to exercise the option or the underlying warrants, the option or warrants, as applicable, expired worthless. As of December 13, 2011, the option had not been exercised and therefore, the option expired. *(d)* *Share repurchase program* On September 15, 2010, the Group announced the authorization of a share repurchase program under which the Company was entitled to repurchase up to US$15 million of its outstanding ordinary shares. Pursuant to this program, the Company was entitled to repurchase its shares for a period of one year commencing on September 15, 2010 in the open market at prevailing market prices or in block trades. On August 3, 2011, the Board of Directors approved the refreshment of the program for 12 months until August 2, 2012. During the year ended March 31, 2012, the Company repurchased and cancelled 2,266,728 ordinary shares at a total cost of RMB44,664. The excess of the repurchase price over par value of RMB44,662 was charged to additional paid-in capital for the year ended March 31, 2012. On July 31, 2012, the Board of Directors approved a new US$20 million share repurchase program to replace the previous US$15 million share repurchase program that expired. During the year ended March 31, 2013, the Company repurchased 7,450,914 ordinary shares at a total cost of RMB131,302 of which 7,314,015 shares were subsequently sold to CGL (Note 1(b)). The remaining 136,899 repurchased ordinary shares had not been cancelled and therefore were presented as treasury stock in the consolidated balance sheets. On July 24, 2013, the Board of Directors approved a new share repurchase program in the aggregate amount of $20 million for 12 months until July 24, 2014.

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 4.E)

-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 4

-Subparagraph (SAB TOPIC 4.C)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Article 4

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section C

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section E

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(d),(e))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Preferred Stock

-URI http://asc.fasb.org/extlink&oid=6521494

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 15: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 16: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 17: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 18: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph d

-Article 4

Reference 19: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 30

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

+ Details

Revenues

12 Months Ended

Mar. 31, 2014

Revenues

Revenues

16 Revenues

The Group’s revenues are primarily derived from the provision of umbilical cord blood storage and ancillary services.

In view of the fact that the Group operates and manages its business solely in the PRC and services are predominately provided to customers located in the PRC, no geographical segment information is provided.

The Group’s revenues by category are as follows:

	Year ended March 31,
	2012	2013	2014	2014
	RMB	RMB	RMB	US$

Cord blood processing fees	279,481	394,641	403,058	64,837
Cord blood storage fees	98,967	129,455	166,649	26,808
Fees derived from the provision of donated cord blood for transplantation and research and others	2,042	2,027	3,150	507
Total revenues	380,490	526,123	572,857	92,152

Income tax

12 Months Ended

Mar. 31, 2014

Income tax

Income tax

17 Income tax

Cayman Islands and British Virgin Islands

Under the current laws of the Cayman Islands and the British Virgin Islands, the Company and its subsidiaries that are incorporated in the Cayman Islands and the British Virgin Islands are not subject to tax on income or capital gains. In addition, upon payments of dividends by these companies, no Cayman Islands or British Virgin Islands withholding tax will be imposed.

Hong Kong

The Company’s subsidiaries that are incorporated or operate in Hong Kong are subject to Hong Kong Profits Tax on income arising in or derived from Hong Kong. No provision was made for Hong Kong Profits Tax as the subsidiaries did not earn income subject to Hong Kong Profits Tax for the years ended March 31, 2012, 2013 and 2014. The payments of dividends by Hong Kong tax residents are not subject to any Hong Kong withholding tax.

The PRC

On March 16, 2007, the Fifth Plenary Session of the Tenth National People’s Congress passed the Corporate Income Tax Law of the PRC (the “new tax law”), which revised the PRC statutory income tax rate to 25% effective on January 1, 2008. The Company’s PRC subsidiaries are subject to income tax at 25% unless otherwise specified.

The new tax law and its relevant regulations provide a five-year transition period for Beijing Jiachenhong which was established before March 16, 2007 and entitled to a preferential income tax rate of 15% under the then effective tax laws or regulations. The transitional tax rates are, 20%, 22%, 24% and 25% for calendar years 2009, 2010, 2011 and 2012 onwards, respectively. In addition, entities that qualify as “High and New Technology Enterprises” (“HNTE”) under the new tax law are entitled to a preferential income tax rate of 15%. Because of its HNTE status, Beijing Jiachenhong was entitled to the reduced tax rate of 15% from January 1, 2008 to December 31, 2010. In February 2012, Beijing Jiachenhong received approval from the tax authority on the renewal of its HNTE status which entitled it to the preferential income tax rate of 15% effective retroactively from January 1, 2011 to December 31, 2013. Subject to reapplication, Beijing Jiachenhong’s HNTE status will enable it to the preferential income tax rate of 15% from January 1, 2014 to December 31, 2016. Management believes that Beijing Jiachenhong meets all the criteria required in connection with the reapplication of HNTE status and therefore applied 15% when recognizing current tax.

In June 2011, Guangzhou Nuoya received approval from the tax authority that it qualified as a HNTE which entitled it to the preferential income tax rate of 15% effective retrospectively from January 1, 2010 to December 31, 2012. As a result, Guangzhou Nuoya received a tax refund in the year ended March 31, 2012, amounting to RMB10,433 in relation to overpaid income tax for the period from January 2010 to December 2010. In April 2014, Guangzhou Nuoya received approval from the tax authority on the renewal of its HNTE status which entitled it to the preferential income tax rate of 15% effective retroactively from January 1, 2013 to December 31, 2015.

The new tax law and its implementation rules also impose a withholding tax at 10%, unless reduced by a tax treaty or agreement, for dividends receivable by non-PRC-resident enterprises from PRC-resident enterprises in respect of earnings accumulated beginning on January 1, 2008. As of March 31, 2014, the Company has provided RMB3,900 (US$627) for withholding income tax on a portion of the undistributed earnings of its PRC subsidiaries according to management’s reinvestment plan. No income taxes were provided for the remaining undistributed earnings which are intended to be reinvested indefinitely in the PRC. As of March 31, 2014, such unremitted earnings that may be subject to the withholding tax amounted to RMB758,698 (US$122,048) and the related unrecognized deferred tax liability was RMB75,870 (US$12,205).

Income before income tax expense arose from the following tax jurisdictions:

	Year ended March 31,
	2012		2013		2014		2014
	RMB		RMB		RMB		US$

The PRC	179,654		260,462		316,933		50,982
Non-PRC	(28,055	)	(102,277	)	(126,009	)	(20,270	)
Income before income tax expense	151,599		158,185		190,924		30,712

(a) Income taxes

Income tax expense represents PRC income tax expense as follows:

	Year ended March 31,
	2012		2013		2014	2014
	RMB		RMB		RMB	US$

Current tax expense	14,405		38,737		50,000	8,043
Deferred tax benefit	(4,771	)	(194	)	8,398	1,351
Total income tax expense	9,634		38,543		58,398	9,394

(b) Reconciliation of expected income tax to actual income tax expense

The actual income tax expense reported in the consolidated statements of comprehensive income differs from the amount computed by applying the statutory PRC income tax rate of 25% for the following reasons:

	Year ended March 31,
	2012		2013		2014		2014
	RMB		RMB		RMB		US$

Income before income tax expense	151,599		158,185		190,924		30,712

Computed “expected” tax expense	37,900		39,546		47,731		7,678
Non-PRC entities not subject to income tax	7,014		25,569		31,502		5,068
PRC dividend withholding tax	—		—		9,887		1,590
Non-taxable income	(1,804	)	—		(1,874	)	(301	)
Effect of change in tax rates	(14,674	)	—		—		—
Tax rate differential, preferential rate	(19,779	)	(26,015	)	(29,011	)	(4,667	)
Others	977		(557	)	163		26
Actual income tax expense	9,634		38,543		58,398		9,394

(c) Deferred taxes

The tax effects of temporary differences that give rise to deferred tax assets/(liabilities) are presented below:

	March 31,
	2013		2014		2014
	RMB		RMB		US$
Deferred tax assets:
Accounts receivable	4,719		6,812		1,096
Non-current accounts receivable	5,754		6,406		1,030
Property, plant and equipment	1,616		—		—
Inventories	2,513		2,293		369
Tax loss	2,011		—		—
Others	798		1,226		197
Net deferred tax assets	17,411		16,737		2,692

Deferred tax liabilities:
Deferred revenue	(105	)	(96	)	(15	)
Property, plant and equipment	—		(4,988	)	(802	)
PRC dividend withholding tax	—		(3,900	)	(627	)
Intangible assets	(31,293	)	(30,138	)	(4,848	)
Deferred tax liabilities	(31,398	)	(39,122	)	(6,292	)

Net deferred tax liabilities	(13,987	)	(22,385	)	(3,600	)

Classification on consolidated balance sheets
Current deferred tax assets	5,454		7,664		1,233
Current deferred tax liabilities	—		(3,900	)	(627	)
Non-current deferred tax assets	3,727		1,789		288
Non-current deferred tax liabilities	(23,168	)	(27,938	)	(4,494	)
Net deferred tax liabilities	(13,987	)	(22,385	)	(3,600	)

For the years ended March 31, 2012, 2013 and 2014, the Group did not have any material unrecognized tax benefits and thus no interest and penalties related to unrecognized tax benefits were recorded. In addition, the Company does not expect that the amount of unrecognized tax benefits will change significantly within the next twelve months.

According to the PRC Tax Administration and Collection Law, the statute of limitation is three years if the underpayment of taxes is due to computational errors made by the taxpayer or the withholding agent. The statute of limitation is extended to five years under special circumstances where the underpayment of taxes is more than RMB100 (US$16). In the case of transfer pricing issues, the statute of limitation is ten years. There is no statute of limitation in the case of tax evasion. The income tax returns of the Group’s PRC subsidiaries for the calendar years from 2009 to 2013 are open to examination by the PRC state and local tax authorities.

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References+ Details

Share-based compensation	12 Months Ended
Share-based compensation	Mar. 31, 2014
Share-based compensation
Share-based compensation	18 Share-based compensation On February 18, 2011, the shareholders of the Company approved and adopted the Restricted Share Unit scheme. The scheme has a limit of granting rights to receive ordinary shares not exceeding 10% of the Company’s issued and outstanding share capital, to directors, officers, employees and/or consultants of the Group. Since no awards have been granted under this scheme, no compensation expense has been recognized for the years ended March 31, 2012, 2013 and 2014.

- Definition

The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.

+ References+ Details

Net income per share

12 Months Ended

Mar. 31, 2014

Net income per share

Net income per share

19 Net income per share

The following table sets forth the computation of basic net income per share and diluted net income per share for the years ended March 31, 2012, 2013 and 2014:

		Year ended March 31,
	Note	2012	2013		2014		2014
		RMB	RMB		RMB		US$
Numerator:
Net income attributable to the Company		131,980	112,447		131,903		21,218
Earnings allocated to participating convertible notes	(i)	—	(6,053	)	(15,050	)	(2,421	)

Net income for basic and diluted net income per share		131,980	106,394		116,853		18,797

Denominator:
Weighted average ordinary shares outstanding for basic and diluted net income per share		73,897,177	71,527,698		73,003,248		73,003,248

Net income per share attributable to ordinary shares:
- Basic		1.79	1.49		1.60		0.26
- Diluted	(ii)	1.79	1.49		1.60		0.26

Notes:

(i) The KKR Notes and GM Notes provide KKRCHIL and GMHL with the ability to participate in any excess cash dividend. Excess cash dividend means any cash dividend to holders of shares that, together with all other cash dividends previously paid to holders of shares in the same financial year, exceeds, on a per share basis, an amount equal to the interest that has accrued and shall accrue at 7% coupon interest rate in such financial year divided by the number of shares into which the notes are convertible at the conversion price then in effect on the relevant record date. Therefore, net income attributable to the Company is reduced by such allocated earnings to participating convertible notes for the years ended March 31, 2013 and 2014 in both basic and diluted net income per share computation.

(ii) During the years ended March 31, 2013 and 2014, the Company had potentially dilutive ordinary shares of 40,521,495 representing shares issuable upon conversion of the KKR Notes and GM Notes (see Note 14). Such potentially dilutive ordinary shares were excluded from diluted net income per share computation because their effects would have been anti-dilutive.

- Definition

The entire disclosure for earnings per share.

+ References+ Details

Related party transactions

12 Months Ended

Mar. 31, 2014

Related party transactions

Related party transactions

20 Related party transactions

For the years presented, the principal related party transactions and amounts due to related parties are summarized as follows:

		Year ended March 31,
	Note	2012	2013	2014	2014
		RMB	RMB	RMB	US$

Rental of properties	(i)	1,440	1,440	1,440	232
Raw material purchase	(ii)	—	—	14,336	2,306
Consultancy expenses	(iii)	—	—	904	145
Interest expenses	14	—	18,761	37,994	6,112

		March 31,
	Note	2013	2014	2014
		RMB	RMB	US$

Current liabilities
Amounts due to related parties	(i),(ii)&14	11,241	21,453	3,452

Note:

(i) During the years ended March 31, 2012, 2013 and 2014, Beijing Jingjing Medical Equipment Co., Ltd. (“Beijing Jingjing”), a subsidiary of GMHL, leased a property to the Group under an operating lease. The monthly rental was RMB174 and renewed at a monthly rental of RMB120 (US$19) effective from July 2009. The lease runs for a period of 5.5 years expiring in December 2014 and does not include contingent rentals.

(ii) During the year ended March 31, 2014, the Company purchased raw materials in the amount of RMB14,336 (US$2,306) from China Bright Group Co. Limited, a subsidiary of GMHL.

(iii) During the year ended March 31, 2014, the Company incurred a consultancy expenses payable to Golden Meditech (S) Pte Ltd., a subsidiary of GMHL, for an amount of RMB904 (SGD200).

- Definition

The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.

+ References+ Details

Pension and other postretirement benefits	12 Months Ended
Pension and other postretirement benefits	Mar. 31, 2014
Pension and other postretirement benefits
Pension and other postretirement benefits	21 Pension and other postretirement benefits Pursuant to the relevant PRC regulations, Beijing Jiachenhong, Guangzhou Nuoya and Zhejiang Lukou are required to make contributions for each employee at a rate of approximately 20% on a standard salary base as determined by the local Social Security Bureau, to a defined contribution retirement scheme organized by the local Social Security Bureau. The amounts of contributions of RMB9,682, RMB12,158 and RMB14,337 (US$2,306) for the years ended March 31, 2012, 2013 and 2014, respectively, were charged to expense in the consolidated statements of comprehensive income. The Group has no other obligation to make payments in respect of retirement benefits of the employees.

- Definition

The entire disclosure for pension and other postretirement benefits.

+ References+ Details

Fair value measurements	12 Months Ended
Fair value measurements	Mar. 31, 2014
Fair value measurements
Fair value measurements	22 Fair value measurements The following methods and assumptions were used to estimate the fair value of each class of financial instruments: The fair value of available-for-sale equity securities is based on quoted market prices on the last trading value as of March 31, 2014. Such investments are classified as Level 1 in the hierarchy. Short-term financial instruments (including cash and cash equivalents, accounts receivable, accounts payable, accrued expenses, other receivables/payables, amounts due to related parties, and short-term bank loan) - cost approximates their respective fair values due to their short-term nature. Convertible notes - the estimated fair value was US$176,640 (RMB1,098,065) based on the level 3 valuation technique as compared to a carrying value of RMB777,753 (US$125,113) as of March 31, 2014. The estimated fair value of the convertible notes is based on a mark-to-model valuation model. Due to the fact that there is no active market for this instrument, the fair value of the convertible notes was estimated using a discounted cash flow analysis based on current borrowing rates for instruments with similar terms. In addition, the Company utilized other sources of information for the relevant market parameters in order to develop its fair value.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References+ Details

Business and credit concentrations

12 Months Ended

Mar. 31, 2014

Business and credit concentrations

Business and credit concentrations

23 Business and credit concentrations

All of the Group’s customers are located in the PRC. Revenues from and gross accounts receivable due from customers are individually immaterial.

The Group purchases raw materials from a few major suppliers. The following are purchases from suppliers that individually comprise 10% or more of gross purchases in the respective years:

	Year ended March 31,
Supplier	2012		2013		2014		2014
	RMB	%	RMB	%	RMB	%	US$	%

Shanghai Qiangzhi Biological Technology Co., Ltd.	3,619	11	11,152	22	7,195	11	1,157	11
Hangzhou Baitong Biological Technology Co., Ltd.	5,490	16	7,783	15	—	—	—	—
Cesca Therapeutics Inc.	—	—	—	—	10,841	17	1,744	17
China Bright Group Co. Limited	—	—	—	—	14,336	23	2,306	23
Beijing Zhu You Ying Kang Technology Development Co., Ltd.	8,340	25	—	—	—	—	—	—
Beijing Probe Biological Technology Co., Ltd.	3,389	10	—	—	—	—	—	—
Total	20,838	62	18,935	37	32,372	51	5,207	51

As of March 31, 2013 and 2014, there is no individual accounts payable due to major suppliers exceeded 10% of outstanding accounts payable balance.

- Definition

The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.

+ References+ Details

Commitments and contingencies

12 Months Ended

Mar. 31, 2014

Commitments and contingencies

Commitments and contingencies

24 Commitments and contingencies

(a) Operating lease commitments

For the years ended March 31, 2012, 2013 and 2014, total rental expenses for operating leases were RMB7,205, RMB4,666 and RMB3,735 (US$601), respectively.

During the year ended March 31, 2013, the Group completed the purchase of the previously leased property in the Guangdong province and terminated the previous lease contract (Note 6).

The total future minimum payments under non-cancellable operating leases as of March 31, 2014 are as follows:

	March 31, 2014
	RMB	US$

Fiscal year ending March 31,
2015	1,780	286
2016	156	25
2017	72	12
Total payments	2,008	323

(b) Contractual commitments

The Group entered into an agreement with an institution for the research and development of medicines for treatments which make use of cord blood stem cells. Commitments as of March 31, 2014 under this agreement amount to RMB2,000 (US$322) (2013: RMB2,000).

In June 2006, the Group entered into a cooperation agreement with Peking University People’s Hospital (“PUPH”). Pursuant to the agreement, PUPH provides technical consultancy services to the Group in relation to the operation of a cord blood bank. The yearly service fee was RMB2,000 and renewed at a yearly service fee of RMB2,600 (US$418) effective from October 2013. The renewed agreement has a term of twenty years commencing in October 2013.

In November 2009, Guangzhou Nuoya entered into a cooperation agreement with Guangdong Women and Children’s Hospital and Health Institute (“GWCH”). Pursuant to the agreement, GWCH provides technical consultancy services to the Group. The yearly service fee was RMB2,000 and renewed at a yearly service fee of RMB3,200 (US$515) effective from October 2013.

In December 2010, Zhejiang Lukou entered into a cooperation agreement with Zhejiang Provincial Blood Center (“ZPBC”) for a term of three years. Pursuant to the agreement, ZPBC provides technical consultancy services and assistances to the Group in return for an annual advisory fee of RMB2,000 (US$322). As of July 31, 2014, the Group is in the process of renewing the agreement.

As of March 31, 2014, the total future minimum payments under the cooperation agreements are as follows:

	March 31, 2014
	RMB	US$

Fiscal year ending March 31,
2015	5,800	933
2016	5,800	933
2017	5,800	933
2018	5,800	933
2019	5,800	933
2020 and thereafter	71,567	11,513
Total payments	100,567	16,178

- Definition

The entire disclosure for commitments and contingencies.

+ References+ Details

Summary of significant accounting policies (Policy)

12 Months Ended

Mar. 31, 2014

Summary of significant accounting policies

Principles of consolidation

(a) Principles of consolidation

Use of estimates

(b) Use of estimates

Foreign currency transactions and translation

(c) Foreign currency transactions and translation

The reporting currency of the Company is Renminbi (“RMB”).

Cash and cash equivalents

(d) Cash and cash equivalents

	March 31,
	2013		2014
	Foreign currency	RMB	Foreign currency	RMB
U.S. dollars	1,451	9,012	398	2,474
Australian dollars	137	895	242	1,378
Renminbi	1,469,512	1,469,512	1,812,025	1,812,025
Hong Kong dollars	17,820	14,542	81,188	64,503
Singapore dollars	27	138	515	2,521

Investment securities

(e) Investment securities

Management determines the appropriate classification of its investment securities at the time of purchase and reevaluates such designations at each reporting date.

Dividend income is recognized in other income when earned.

Accounts receivable

(f) Accounts receivable

Inventories

(g) Inventories

Property, plant and equipment

(h) Property, plant and equipment

Property, plant and equipment are stated at cost less accumulated depreciation.

Buildings	37.5 – 50 years
Leasehold improvements	Shorter of the lease term or estimated useful lives of 10 years
Machineries	5 – 10 years
Motor vehicles	5 years
Furniture, fixtures and office equipment	3 – 5 years

No depreciation expense is provided in respect of construction-in-progress.

Intangible assets

(i) Intangible assets

Impairment of long-lived assets

(j) Impairment of long-lived assets

Revenue recognition

(k) Revenue recognition

Pursuant to the Agreement, no penalty is charged to customers for early termination of the storage service.

The Group considers all reasonably available information to allocate the overall arrangement fee to processing and storage services based on their relative selling prices.

During the three years ended March 31, 2012, 2013 and 2014, the Group offered its customers three payment options:

(i) Payment of the processing fee upon delivery of the cord blood unit to the Group’s premises for processing and the annual storage fee in advance at the beginning of each one-year renewal period;

(ii) Payment of the processing fee upon delivery of the cord blood unit to the Group’s premises for processing and prepayment of storage fees for multiple periods; and

Research and development costs

(l) Research and development costs

Advertising and promotion costs

(m) Advertising and promotion costs

Retirement and other postretirement benefits

(n) Retirement and other postretirement benefits

Debt issuance costs

(o) Debt issuance costs

Income taxes

(p) Income taxes

Commitments and contingencies

(q) Commitments and contingencies

Earnings per share

(r) Earnings per share

Share option plan

(s) Share option plan

Segment reporting

(t) Segment reporting

Fair value measurement

(u) Fair value measurement

· Level 1 Inputs: Unadjusted quoted prices in active markets for identical assets or liabilities accessible to the reporting entity at the measurement date.

The Group did not have any non-financial assets or liabilities that are measured at fair value on a recurring basis as of March 31, 2012, 2013 and 2014.

See Note 22 to the consolidated financial statements.

Recently issued accounting standards

(v) Recently issued accounting standards

Summary of significant accounting policies (Tables)

12 Months Ended

Mar. 31, 2014

Summary of significant accounting policies

Schedule of Cash and Cash Equivalents Denominated in Currencies

A majority of the Group’s cash and cash equivalents are denominated in U.S. dollars, Australian dollars, Renminbi, Hong Kong dollars and Singapore dollars as follows:

	March 31,
	2013		2014
	Foreign currency	RMB	Foreign currency	RMB
U.S. dollars	1,451	9,012	398	2,474
Australian dollars	137	895	242	1,378
Renminbi	1,469,512	1,469,512	1,812,025	1,812,025
Hong Kong dollars	17,820	14,542	81,188	64,503
Singapore dollars	27	138	515	2,521

Schedule of Depreciation of Property, Plant and Equipment

Buildings	37.5 – 50 years
Leasehold improvements	Shorter of the lease term or estimated useful lives of 10 years
Machineries	5 – 10 years
Motor vehicles	5 years
Furniture, fixtures and office equipment	3 – 5 years

Accounts receivable, net (Tables)

12 Months Ended

Mar. 31, 2014

Accounts receivable, net

Schedule of Accounts Receivable

	March 31,
	2013		2014		2014
	RMB		RMB		US$

Accounts receivable	372,919		383,794		61,739
Less: Allowance for doubtful accounts	(50,473	)	(63,025	)	(10,138	)
Total accounts receivable, net	322,446		320,769		51,601

Representing:

Current portion:
- processing fees	49,092		64,838		10,430
- storage fees	23,357		28,894		4,648
- others	627		1,541		248
	73,076		95,273		15,326
Non-current portion:
- processing fees	249,370		225,496		36,275
Total accounts receivable, net	322,446		320,769		51,601

Schedule of Non-Current Gross Accounts Receivable, Minimum Payments

	March 31, 2014
	RMB	US$
Fiscal years ending March 31,
2016	35,442	5,701
2017	32,161	5,174
2018	28,363	4,563
2019	25,537	4,108
2020 and thereafter	146,696	23,598
	268,199	43,144

Schedule of Allowance for Doubtful Accounts

	Year ended March 31,
	2012	2013		2014		2014
	RMB	RMB		RMB		US$

Balance at beginning of year	39,956	52,544		50,473		8,119
Charged to allowance for doubtful accounts	12,588	7,468		17,973		2,891
Write-off charged against the allowance for the year		(9,539	)	(5,421	)	(872	)
Balance at end of year	52,544	50,473		63,025		10,138

Inventories (Tables)

12 Months Ended

Mar. 31, 2014

Inventories

Schedule of Inventories

	March 31,
	2013	2014	2014
	RMB	RMB	US$

Current portion:
- consumables and supplies	10,265	31,583	5,080

Non-current portion:
- processing costs capitalized in donated umbilical cord blood	39,730	48,385	7,783
Total current and non-current inventories	49,995	79,968	12,863

Prepaid expenses and other receivables (Tables)

12 Months Ended

Mar. 31, 2014

Prepaid expenses and other receivables

Schedule of Prepaid Expenses and Other Receivables

	March 31,
	2013	2014	2014
	RMB	RMB	US$

Prepaid expenses	9,372	20,593	3,313
Tax receivables	—	13,406	2,157
Other receivables	2,230	3,011	484
Total prepaid expenses and other receivables	11,602	37,010	5,954

Property, plant and equipment, net (Tables)

12 Months Ended

Mar. 31, 2014

Property, plant and equipment, net

Schedule of Property, Plant and Equipment, Net

	March 31,
	2013		2014		2014
	RMB		RMB		US$

Buildings	187,529		578,513		93,064
Leasehold improvements	44,264		14,864		2,391
Machineries	105,899		118,449		19,054
Motor vehicles	11,087		14,885		2,394
Furniture, fixtures and office equipment	27,588		35,433		5,700
Construction-in-progress	205,657		9,684		1,558
	582,024		771,828		124,161
Less: Accumulated depreciation	(113,752	)	(145,196	)	(23,357	)
Total property, plant and equipment, net	468,272		626,632		100,804

Schedule of Depreciation Expense of Property, Plant and Equipment

	Year ended March 31,
	2012	2013	2014	2014
	RMB	RMB	RMB	US$

Direct costs	13,481	17,421	18,150	2,920
Research and development	3,212	2,073	1,863	300
Sales and marketing	1,803	2,805	2,611	419
General and administrative	6,240	8,954	9,820	1,580
Total depreciation expense	24,736	31,253	32,444	5,219

Schedule of interest cost incurred

	Year ended March 31,
	2012	2013	2014	2014
	RMB	RMB	RMB	US$

Interest cost capitalized	—	1,274	25,912	4,168
Interest cost charged to income	3,287	70,097	70,075	11,273
Total interest cost incurred	3,287	71,371	95,987	15,441

Non-current prepayments (Tables)

12 Months Ended

Mar. 31, 2014

Non-current prepayments

Schedule of Non-Current Prepayments

		March 31,
	Note	2013	2014	2014
		RMB	RMB	US$

Investment deposit	(i)	212,188	208,591	33,555
Deposit for machineries purchase		445	303	49
Total non-current prepayments		212,633	208,894	33,604

Note:

Intangible assets, net (Tables)

12 Months Ended

Mar. 31, 2014

Intangible assets, net

Schedule of Components of Intangible Assets, Net

	March 31,
	2013		2014		2014
	RMB		RMB		US$

Cord blood bank operating rights	138,628		138,628		22,300
Less: Accumulated amortization	(13,458	)	(18,079	)	(2,908	)
Total intangible assets, net	125,170		120,549		19,392

Schedule of Estimated Amortization Expenses

Estimated amortization expenses for the years afterwards are:

	March 31, 2014
	RMB	US$
Fiscal years ending March 31,
2015	4,621	743
2016	4,621	743
2017	4,621	743
2018	4,621	743
2019 and thereafter	102,065	16,420
Total amortization expenses	120,549	19,392

Available-for-sale equity securities (Tables)

12 Months Ended

Mar. 31, 2014

Available-for-sale equity securities

Schedule of Available-for-Sale Equity Securities

	March 31,
	2013	2014	2014
	RMB	RMB	US$

Life Corporation Limited - listed on Australian Securities Exchange	8,284	4,630	745
Cordlife Group Limited - listed on Singapore Exchange	80,120	139,617	22,459
Total listed equity securities, at market	88,404	144,247	23,204

- Definition

Tabular disclosure of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.

+ References+ Details

Other investment (Tables)

12 Months Ended

Mar. 31, 2014

Other investment

Schedule of Other Investment

	March 31,
	2013	2014	2014
	RMB	RMB	US$

Unlisted equity securities, at cost	189,129	189,129	30,424

Accrued expenses and other payables (Tables)

12 Months Ended

Mar. 31, 2014

Accrued expenses and other payables

Schedule of Accrued Expenses and Other Payables

		March 31,
	Note	2013	2014	2014
		RMB	RMB	US$

Insurance premiums received on behalf of an insurance company	(i)	12,411	15,292	2,460
Other taxes payables		1,616	3,927	632
Accrued salaries, bonus and welfare expenses		17,828	23,005	3,701
Accrued consultancy and professional fees		7,770	3,599	579
Payable for convertible notes interests	(ii)	26,639	26,188	4,213
Payable for debt issuance costs		3,242	—	—
Payable for property, plant and equipment	(iii)	—	15,969	2,569
Other payables	(iv)	14,500	14,579	2,344
Total accrued expenses and other payables		84,006	102,559	16,498

Notes:

(iii) Payable for property, plant and equipment related to the amount payable for the development and renovation of the newly purchased properties (Note 6).

(iv) Other payables mainly include fee refundable to customers whose cord blood unit does not qualify for subsequent storage and other operating procurement payables.

Deferred revenue (Tables)

12 Months Ended

Mar. 31, 2014

Deferred revenue

Schedule of Deferred Revenue

	March 31,
	2013	2014	2014
	RMB	RMB	US$

Prepayments by customers prior to completion of cord blood processing services	94,471	93,597	15,056
Unearned storage fees	608,115	926,756	149,083
Total current and non-current deferred revenue	702,586	1,020,353	164,139

Representing:
Current portion	172,328	196,432	31,599
Non-current portion	530,258	823,921	132,540
Total current and non-current deferred revenue	702,586	1,020,353	164,139

Schedule of Unearned Storage Fees

	Year ended March 31,
	2012		2013		2014		2014
	RMB		RMB		RMB		US$

Balance at beginning of year	199,470		361,034		608,115		97,824
Deferred revenue arising from new customers	260,531		376,536		485,290		78,067
Credited to income	(98,967	)	(129,455	)	(166,649	)	(26,808	)
Balance at end of year	361,034		608,115		926,756		149,083

Convertible notes (Tables)

12 Months Ended

Mar. 31, 2014

Convertible notes

Schedule of Convertible Notes

	March 31,
	2013	2014	2014
	RMB	RMB	US$

Principal amount of the KKR Notes	409,764	403,315	64,879
Principal amount of the GM Notes	315,226	310,302	49,917
Cumulative interest payables	26,791	64,136	10,317
Carrying amount	751,781	777,753	125,113

Schedule of Interest Relating to KKR Notes and GM Notes

	Year ended March 31,
	2013		2014		2014
	RMB		RMB		US$

KKR Notes interest incurred	45,959		50,475		8,120
GM Notes interest incurred	18,761		37,994		6,112
Amortization of debt issuance costs	3,062		3,610		581
Notes related interest cost capitalized	(1,207	)	(24,822	)	(3,993	)
Total interest expense	66,575		67,257		10,820

Revenues (Tables)

12 Months Ended

Mar. 31, 2014

Revenues

Schedule of Revenue from External Customers

	Year ended March 31,
	2012	2013	2014	2014
	RMB	RMB	RMB	US$

Cord blood processing fees	279,481	394,641	403,058	64,837
Cord blood storage fees	98,967	129,455	166,649	26,808
Fees derived from the provision of donated cord blood for transplantation and research and others	2,042	2,027	3,150	507
Total revenues	380,490	526,123	572,857	92,152

Income tax (Tables)

12 Months Ended

Mar. 31, 2014

Income tax

Schedule of Income before Income Tax Expense

	Year ended March 31,
	2012		2013		2014		2014
	RMB		RMB		RMB		US$

The PRC	179,654		260,462		316,933		50,982
Non-PRC	(28,055	)	(102,277	)	(126,009	)	(20,270	)
Income before income tax expense	151,599		158,185		190,924		30,712

Schedule of Income Tax (Benefit) Expense

	Year ended March 31,
	2012		2013		2014	2014
	RMB		RMB		RMB	US$

Current tax expense	14,405		38,737		50,000	8,043
Deferred tax benefit	(4,771	)	(194	)	8,398	1,351
Total income tax expense	9,634		38,543		58,398	9,394

Schedule of the Reconciliation between the Statutory rate and the Effective tax rate

	Year ended March 31,
	2012		2013		2014		2014
	RMB		RMB		RMB		US$

Income before income tax expense	151,599		158,185		190,924		30,712

Computed “expected” tax expense	37,900		39,546		47,731		7,678
Non-PRC entities not subject to income tax	7,014		25,569		31,502		5,068
PRC dividend withholding tax	—		—		9,887		1,590
Non-taxable income	(1,804	)	—		(1,874	)	(301	)
Effect of change in tax rates	(14,674	)	—		—		—
Tax rate differential, preferential rate	(19,779	)	(26,015	)	(29,011	)	(4,667	)
Others	977		(557	)	163		26
Actual income tax expense	9,634		38,543		58,398		9,394

Schedule of Deferred Tax Assets and Liabilities

	March 31,
	2013		2014		2014
	RMB		RMB		US$
Deferred tax assets:
Accounts receivable	4,719		6,812		1,096
Non-current accounts receivable	5,754		6,406		1,030
Property, plant and equipment	1,616		—		—
Inventories	2,513		2,293		369
Tax loss	2,011		—		—
Others	798		1,226		197
Net deferred tax assets	17,411		16,737		2,692

Deferred tax liabilities:
Deferred revenue	(105	)	(96	)	(15	)
Property, plant and equipment	—		(4,988	)	(802	)
PRC dividend withholding tax	—		(3,900	)	(627	)
Intangible assets	(31,293	)	(30,138	)	(4,848	)
Deferred tax liabilities	(31,398	)	(39,122	)	(6,292	)

Net deferred tax liabilities	(13,987	)	(22,385	)	(3,600	)

Classification on consolidated balance sheets
Current deferred tax assets	5,454		7,664		1,233
Current deferred tax liabilities	—		(3,900	)	(627	)
Non-current deferred tax assets	3,727		1,789		288
Non-current deferred tax liabilities	(23,168	)	(27,938	)	(4,494	)
Net deferred tax liabilities	(13,987	)	(22,385	)	(3,600	)

Net income per share (Tables)

12 Months Ended

Mar. 31, 2014

Net income per share

Schedule of Basic and Diluted Net Earnings Per Share

		Year ended March 31,
	Note	2012	2013		2014		2014
		RMB	RMB		RMB		US$
Numerator:
Net income attributable to the Company		131,980	112,447		131,903		21,218
Earnings allocated to participating convertible notes	(i)	—	(6,053	)	(15,050	)	(2,421	)

Net income for basic and diluted net income per share		131,980	106,394		116,853		18,797

Denominator:
Weighted average ordinary shares outstanding for basic and diluted net income per share		73,897,177	71,527,698		73,003,248		73,003,248

Net income per share attributable to ordinary shares:
- Basic		1.79	1.49		1.60		0.26
- Diluted	(ii)	1.79	1.49		1.60		0.26

Notes:

Related party transactions (Tables)

12 Months Ended

Mar. 31, 2014

Related party transactions

Schedule of Related Party Transactions

		Year ended March 31,
	Note	2012	2013	2014	2014
		RMB	RMB	RMB	US$

Rental of properties	(i)	1,440	1,440	1,440	232
Raw material purchase	(ii)	—	—	14,336	2,306
Consultancy expenses	(iii)	—	—	904	145
Interest expenses	14	—	18,761	37,994	6,112

		March 31,
	Note	2013	2014	2014
		RMB	RMB	US$

Current liabilities
Amounts due to related parties	(i),(ii)&14	11,241	21,453	3,452

Note:

(ii) During the year ended March 31, 2014, the Company purchased raw materials in the amount of RMB14,336 (US$2,306) from China Bright Group Co. Limited, a subsidiary of GMHL.

(iii) During the year ended March 31, 2014, the Company incurred a consultancy expenses payable to Golden Meditech (S) Pte Ltd., a subsidiary of GMHL, for an amount of RMB904 (SGD200).

Business and credit concentrations (Tables)

12 Months Ended

Mar. 31, 2014

Business and credit concentrations

Schedule of Major Suppliers

	Year ended March 31,
Supplier	2012		2013		2014		2014
	RMB	%	RMB	%	RMB	%	US$	%

Shanghai Qiangzhi Biological Technology Co., Ltd.	3,619	11	11,152	22	7,195	11	1,157	11
Hangzhou Baitong Biological Technology Co., Ltd.	5,490	16	7,783	15	—	—	—	—
Cesca Therapeutics Inc.	—	—	—	—	10,841	17	1,744	17
China Bright Group Co. Limited	—	—	—	—	14,336	23	2,306	23
Beijing Zhu You Ying Kang Technology Development Co., Ltd.	8,340	25	—	—	—	—	—	—
Beijing Probe Biological Technology Co., Ltd.	3,389	10	—	—	—	—	—	—
Total	20,838	62	18,935	37	32,372	51	5,207	51

- Definition

Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.

+ References+ Details

Commitments and contingencies (Tables)

12 Months Ended

Mar. 31, 2014

Commitments and contingencies

Schedule of Future Minimum Lease Payments

The total future minimum payments under non-cancellable operating leases as of March 31, 2014 are as follows:

	March 31, 2014
	RMB	US$

Fiscal year ending March 31,
2015	1,780	286
2016	156	25
2017	72	12
Total payments	2,008	323

Schedule of Future Minimum Payments Under the Co-Operation Agreements

As of March 31, 2014, the total future minimum payments under the cooperation agreements are as follows:

	March 31, 2014
	RMB	US$

Fiscal year ending March 31,
2015	5,800	933
2016	5,800	933
2017	5,800	933
2018	5,800	933
2019	5,800	933
2020 and thereafter	71,567	11,513
Total payments	100,567	16,178

Principal activities, reorganization and reverse recapitalization, and basis of presentation (Details)	1 Months Ended		12 Months Ended				1 Months Ended		0 Months Ended		1 Months Ended		1 Months Ended			1 Months Ended
	Nov. 30, 2012 USD ($)	Nov. 30, 2012 CNY	Mar. 31, 2013 CNY	Mar. 31, 2012 CNY	Mar. 31, 2014 item	Mar. 31, 2014 PRC item	Feb. 28, 2011 Zhejiang Province USD ($)	Feb. 28, 2011 Zhejiang Province CNY	Nov. 03, 2008 China Cord Blood Services (CCBS) Share Exchange Agreement USD ($)	Jun. 30, 2009 China Cord Blood Services (CCBS) Share Exchange Agreement	Aug. 31, 2009 China Cord Blood Services (CCBS) Agreements for remaining shares	Jan. 31, 2008 China Stem Cells Holdings Limited (CSC Holdings) PRC item	Nov. 30, 2012 China Stem Cells (South) Company Limited USD ($)	Nov. 30, 2012 China Stem Cells (South) Company Limited CNY	May 31, 2007 China Stem Cells (South) Company Limited	May 31, 2007 China Stem Cells (South) Company Limited Guangzhou Nuoya CNY	Dec. 31, 2010 Zhejiang Lukou CNY
Principal activities, reorganization and reverse recapitalization, and basis of presentation
Number of cord blood banking licenses issued					7
Number of cord blood banking licenses issued that are held by the Company					3
Subsidiary or Equity Method Investee
Maximum number of shares of Company common stock issuable under agreement									57,851,240
Percentage of acquiree's ordinary shares sold to Company									100.00%
Percentage of acquiree's redeemable ordinary shares sold to Company									76.00%		24.00%
Percentage of equity interests in acquiree sold to Company									93.94%
Consideration									$ 328,790,000
Shares of Company common stock issued as consideration									54,345,104		3,506,136
Value per share of consideration									$ 6.05
Percentage of equity interest in subsidiary															90.00%		90.00%
Consideration received in stock transaction	20,800,000
Treasury shares sold to CGL	7,314,015	7,314,015	7,314,015
Treasury shares sold to CGL, as a percent of the Company's ordinary shares	10.00%	10.00%
Percentage of ownership after transaction										91.70%
Number of main subsidiaries						3						2
Payments to acquire interest in subsidiary																30,949,000
Payment for repurchase of common stock				44,664,000									16,800,000
Net proceeds from sale of equity	4,000,000	25,320,000	25,320,000
Consideration for operating rights							12,500,000	82,124,000
Capital injection from Group																	45,000,000
Credit to additional paid-in capital on reissuance of treasury stock		3,341,000
Charge to paid-in capital for shares repurchased														70,774,000
Ownership interest by noncontrolling owner																	10.00%
Percentage of shares repurchased													10.00%	10.00%
Contribution of property from non-controlling interests																	5,000,000

Summary of significant accounting policies (Details 2) In Thousands, unless otherwise specified	12 Months Ended
	Mar. 31, 2014 USD ($)	Mar. 31, 2014 CNY	Mar. 31, 2013 USD ($)	Mar. 31, 2013 CNY	Mar. 31, 2012 CNY	Mar. 31, 2011 CNY	Mar. 31, 2014 PRC USD ($)	Mar. 31, 2014 PRC CNY	Mar. 31, 2013 PRC CNY	Mar. 31, 2014 U.S. dollar USD ($)	Mar. 31, 2014 U.S. dollar CNY	Mar. 31, 2013 U.S. dollar USD ($)	Mar. 31, 2013 U.S. dollar CNY	Mar. 31, 2014 Australian dollars AUD	Mar. 31, 2014 Australian dollars CNY	Mar. 31, 2013 Australian dollars AUD	Mar. 31, 2013 Australian dollars CNY	Mar. 31, 2014 Renminbi CNY	Mar. 31, 2013 Renminbi CNY	Mar. 31, 2014 Hong Kong dollars CNY	Mar. 31, 2014 Hong Kong dollars HKD	Mar. 31, 2013 Hong Kong dollars CNY	Mar. 31, 2013 Hong Kong dollars HKD	Mar. 31, 2014 Singapore dollars CNY	Mar. 31, 2014 Singapore dollars SGD	Mar. 31, 2013 Singapore dollars CNY	Mar. 31, 2013 Singapore dollars SGD
Cash and Cash Equivalents
Cash and cash equivalents	$ 302,892	1,882,901	$ 240,347	1,494,099	794,311	611,387	$ 291,488	1,812,007	1,470,844	$ 398	2,474	$ 1,451	9,012	242	1,378	137	895	1,812,025	1,469,512	64,503	81,188	14,542	17,820	2,521	515	138	27
Accounts Receivable Additional Disclosures [Abstract]
Threshold age of accounts receivable in order to write-off	3 years	3 years

- Definition

Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.

+ References+ Details

Summary of significant accounting policies (Details 3) In Thousands, unless otherwise specified	12 Months Ended
	Mar. 31, 2014 USD ($)	Mar. 31, 2014 CNY	Mar. 31, 2013 CNY	Mar. 31, 2012 CNY	Mar. 31, 2014 Buildings Minimum	Mar. 31, 2014 Buildings Maximum	Mar. 31, 2014 Leasehold Improvements	Mar. 31, 2014 Machineries Minimum	Mar. 31, 2014 Machineries Maximum	Mar. 31, 2014 Motor Vehicles	Mar. 31, 2014 Furniture, Fixtures and Office Equipment Minimum	Mar. 31, 2014 Furniture, Fixtures and Office Equipment Maximum	Mar. 31, 2014 Construction-in-progress CNY
Property, Plant and Equipment
Estimated useful lives					37 years 6 months	50 years	10 years	5 years	10 years	5 years	3 years	5 years
Depreciation expense	$ 5,219	32,444	31,253	24,736									0

Summary of significant accounting policies (Details 4) In Thousands, unless otherwise specified	12 Months Ended
	Mar. 31, 2014 USD ($) item	Mar. 31, 2014 CNY	Mar. 31, 2013 CNY	Mar. 31, 2012 CNY	Mar. 31, 2014 PRC item
Accounting Policies
Estimated useful life of the operating rights	30 years	30 years
Impairment of long-lived assets		0	0	0
Penalty charged to customers for early termination of the storage service		0
Advertising and promotion costs	$ 4,952	30,785	19,215	12,460
Agreement with customers, blood storage period	18 years	18 years
Agreement with customers, blood storage renewal period	1 year	1 year
Customer delinquent period before ceasing of recognizing storage revenue	24 months	24 months	24 months	24 months
Number of main subsidiaries					3
VAT tax rate, currently applicable	6.00%	6.00%
Business tax rate, no longer applicable	5.00%	5.00%
Debt issuance costs, period charged	5 years	5 years
Number of operating segments	1	1

Accounts receivable, net (Details) In Thousands, unless otherwise specified	Mar. 31, 2014 USD ($)	Mar. 31, 2014 CNY	Mar. 31, 2013 USD ($)	Mar. 31, 2013 CNY	Mar. 31, 2012 CNY	Mar. 31, 2011 CNY	Mar. 31, 2014 Processing fees USD ($)	Mar. 31, 2014 Processing fees CNY	Mar. 31, 2013 Processing fees CNY	Mar. 31, 2014 Storage fees USD ($)	Mar. 31, 2014 Storage fees CNY	Mar. 31, 2013 Storage fees CNY	Mar. 31, 2014 Other USD ($)	Mar. 31, 2014 Other CNY	Mar. 31, 2013 Other CNY
Accounts receivable
Accounts receivable, current portion	$ 15,326	95,273		73,076			$ 10,430	64,838	49,092	$ 4,648	28,894	23,357	$ 248	1,541	627
Accounts receivable, noncurrent portion	36,275	225,496		249,370			36,275	225,496	249,370
Accounts receivable	61,739	383,794		372,919
Less: Allowance for doubtful accounts	(10,138)	(63,025)	(8,119)	(50,473)	(52,544)	(39,956)
Total accounts receivable, net	$ 51,601	320,769		322,446

Accounts receivable, net (Details 2) In Thousands, unless otherwise specified	Mar. 31, 2014 USD ($)	Mar. 31, 2014 CNY
Accounts receivable, net
2016	$ 5,701	35,442
2017	5,174	32,161
2018	4,563	28,363
2019	4,108	25,537
2020 and thereafter	23,598	146,696
Total	$ 43,144	268,199

Accounts receivable, net (Details 3) In Thousands, unless otherwise specified	12 Months Ended
	Mar. 31, 2014 USD ($)	Mar. 31, 2014 CNY	Mar. 31, 2013 CNY	Mar. 31, 2012 CNY
Analysis of the allowance for doubtful accounts
Balance at beginning of year	$ 8,119	50,473	52,544	39,956
Charged to allowance for doubtful accounts	2,891	17,973	7,468	12,588
Write-off charged against the allowance for the year	(872)	(5,421)	(9,539)
Balance at end of year	$ 10,138	63,025	50,473	52,544
Age of accounts receivable written-off	3 years	3 years

Inventories (Details) In Thousands, unless otherwise specified	Mar. 31, 2014 USD ($)	Mar. 31, 2014 CNY	Mar. 31, 2013 CNY	Mar. 31, 2014 Consumables and supplies USD ($)	Mar. 31, 2014 Consumables and supplies CNY	Mar. 31, 2013 Consumables and supplies CNY	Mar. 31, 2014 Processing costs capitalized in donated umbilical cord blood USD ($)	Mar. 31, 2014 Processing costs capitalized in donated umbilical cord blood CNY	Mar. 31, 2013 Processing costs capitalized in donated umbilical cord blood CNY
Inventories
Current portion: - consumables and supplies	$ 5,080	31,583	10,265	$ 5,080	31,583	10,265
Non-current portion: - processing costs capitalized in donated umbilical cord blood	7,783	48,385	39,730				7,783	48,385	39,730
Total current and non-current inventories	$ 12,863	79,968	49,995

Inventories (Details 2) (CNY) In Thousands, unless otherwise specified	12 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2012
Inventories
Provision for inventories	0	0	0
Weighted average remaining useful life of donated cord blood units	19 years
The estimated increase per annum in number of successful matches of donated units (as a percent)	7.00%

- Definition

Amount of valuation reserve for inventory.

+ References+ Details

Prepaid expenses and other receivables (Details) In Thousands, unless otherwise specified	Mar. 31, 2014 USD ($)	Mar. 31, 2014 CNY	Mar. 31, 2013 CNY
Prepaid expenses and other receivables
Prepaid expenses	$ 3,313	20,593	9,372
Tax receivables	2,157	13,406
Other receivables	484	3,011	2,230
Total prepaid expenses and other receivables	$ 5,954	37,010	11,602

- Definition

Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes.

+ References+ Details

Property, plant and equipment, net (Details) In Thousands, unless otherwise specified	Mar. 31, 2014 USD ($)	Mar. 31, 2014 CNY	Mar. 31, 2013 CNY	Mar. 31, 2014 Buildings USD ($)	Mar. 31, 2014 Buildings CNY	Mar. 31, 2013 Buildings CNY	Mar. 31, 2014 Leasehold Improvements USD ($)	Mar. 31, 2014 Leasehold Improvements CNY	Mar. 31, 2013 Leasehold Improvements CNY	Mar. 31, 2014 Machineries USD ($)	Mar. 31, 2014 Machineries CNY	Mar. 31, 2013 Machineries CNY	Mar. 31, 2014 Motor Vehicles USD ($)	Mar. 31, 2014 Motor Vehicles CNY	Mar. 31, 2013 Motor Vehicles CNY	Mar. 31, 2014 Furniture, Fixtures and Office Equipment USD ($)	Mar. 31, 2014 Furniture, Fixtures and Office Equipment CNY	Mar. 31, 2013 Furniture, Fixtures and Office Equipment CNY	Mar. 31, 2014 Construction-in-Progress USD ($)	Mar. 31, 2014 Construction-in-Progress CNY	Mar. 31, 2013 Construction-in-Progress CNY
Property, Plant and Equipment
Property, plant and equipment	$ 124,161	771,828	582,024	$ 93,064	578,513	187,529	$ 2,391	14,864	44,264	$ 19,054	118,449	105,899	$ 2,394	14,885	11,087	$ 5,700	35,433	27,588	$ 1,558	9,684	205,657
Less: Accumulated depreciation	(23,357)	(145,196)	(113,752)
Total property, plant and equipment, net	$ 100,804	626,632	468,272

Property, plant and equipment, net (Details 2) In Thousands, unless otherwise specified	12 Months Ended						12 Months Ended					12 Months Ended			12 Months Ended
	Mar. 31, 2014 USD ($)	Mar. 31, 2014 CNY	Mar. 31, 2013 CNY	Mar. 31, 2014 Buildings Short-term bank loan USD ($)	Mar. 31, 2014 Buildings Short-term bank loan CNY	Mar. 31, 2013 Buildings Short-term bank loan CNY	Mar. 31, 2014 Guangdong Province [Domain] USD ($)	Mar. 31, 2014 Guangdong Province [Domain] CNY	Mar. 31, 2014 Guangdong Province [Domain] Accrued expense and other payables USD ($)	Mar. 31, 2014 Guangdong Province [Domain] Accrued expense and other payables CNY	Jun. 28, 2012 Guangzhou Nuoya CNY	Mar. 31, 2014 Zhejiang Province USD ($)	Mar. 31, 2014 Zhejiang Province CNY	Dec. 31, 2013 Zhejiang Province item	Mar. 31, 2014 Zhejiang Province Accrued expense and other payables USD ($)	Mar. 31, 2014 Zhejiang Province Accrued expense and other payables CNY	Mar. 31, 2013 Zhejiang Province Buildings and associated land use right CNY
Property, Plant and Equipment
Numbers of third party in the purchase contract														2
Purchase price of the property and land use right											107,294
Payments for property, plant and equipment	124,161	771,828	582,024				17,044	105,954	450	2,800		8,441	52,474		1,930	12,000	87,508
Carrying value of buildings collateralized for loans				18,430	114,570	121,603
Bank loan	$ 9,652	60,000	50,000	$ 9,652	60,000	50,000

Property, plant and equipment, net (Details 3) In Thousands, unless otherwise specified	12 Months Ended
	Mar. 31, 2014 USD ($)	Mar. 31, 2014 CNY	Mar. 31, 2013 CNY	Mar. 31, 2012 CNY	Mar. 31, 2014 Direct costs USD ($)	Mar. 31, 2014 Direct costs CNY	Mar. 31, 2013 Direct costs CNY	Mar. 31, 2012 Direct costs CNY	Mar. 31, 2014 Research and development USD ($)	Mar. 31, 2014 Research and development CNY	Mar. 31, 2013 Research and development CNY	Mar. 31, 2012 Research and development CNY	Mar. 31, 2014 Sales and marketing USD ($)	Mar. 31, 2014 Sales and marketing CNY	Mar. 31, 2013 Sales and marketing CNY	Mar. 31, 2012 Sales and marketing CNY	Mar. 31, 2014 General and administrative USD ($)	Mar. 31, 2014 General and administrative CNY	Mar. 31, 2013 General and administrative CNY	Mar. 31, 2012 General and administrative CNY
Property, Plant and Equipment
Depreciation expense	$ 5,219	32,444	31,253	24,736	$ 2,920	18,150	17,421	13,481	$ 300	1,863	2,073	3,212	$ 419	2,611	2,805	1,803	$ 1,580	9,820	8,954	6,240

Property, plant and equipment, net (Details 4) In Thousands, unless otherwise specified	12 Months Ended
	Mar. 31, 2014 USD ($)	Mar. 31, 2014 CNY	Mar. 31, 2013 CNY	Mar. 31, 2012 CNY
Interest cost incurred
Interest cost capitalized	$ 4,168	25,912	1,274
Interest cost charged to income	11,273	70,075	70,097	3,287
Total interest cost incurred	$ 15,441	95,987	71,371	3,287

Non-current prepayments (Details) In Thousands, unless otherwise specified	12 Months Ended
	Mar. 31, 2013 USD ($)	Mar. 31, 2013 CNY	Mar. 31, 2014 USD ($)	Mar. 31, 2014 CNY
Non-current prepayments
Investment deposit		212,188	$ 33,555	208,591
Deposit for machineries purchase		445	49	303
Total non-current prepayments		212,633	33,604	208,894
Earnest deposit for investment remitted	$ 33,660	208,591

Intangible assets, net (Details) In Thousands, unless otherwise specified	Mar. 31, 2014 USD ($)	Mar. 31, 2014 CNY	Mar. 31, 2013 CNY
Intangible assets, net
Cord blood bank operating rights	$ 22,300	138,628	138,628
Less: Accumulated amortization	(2,908)	(18,079)	(13,458)
Total intangible assets, net	$ 19,392	120,549	125,170

Intangible assets, net (Details 2) In Thousands, unless otherwise specified	12 Months Ended								1 Months Ended			12 Months Ended
	Mar. 31, 2014 USD ($)	Mar. 31, 2014 CNY	Mar. 31, 2013 CNY	Mar. 31, 2012 CNY	Mar. 31, 2014 Guangdong Province [Domain] USD ($)	Mar. 31, 2014 Guangdong Province [Domain] CNY	Mar. 31, 2013 Guangdong Province [Domain] CNY	Mar. 31, 2012 Guangdong Province [Domain] CNY	Aug. 31, 2011 Zhejiang Province CNY	Feb. 28, 2011 Zhejiang Province USD ($)	Feb. 28, 2011 Zhejiang Province CNY	Mar. 31, 2014 Zhejiang Province USD ($)	Mar. 31, 2014 Zhejiang Province CNY	Mar. 31, 2013 Zhejiang Province CNY	Mar. 31, 2012 Zhejiang Province CNY
Finite-Lived Intangible Assets
Estimated useful life of operating rights	30 years	30 years
Amortization expense of operating rights	$ 743	4,621	4,621	4,621	$ 156	971	971	971				$ 587	3,650	3,650	3,650
Consideration for operating rights										12,500	82,124
Value of acquired operating rights									109,499
Deferred tax liability	$ 4,848	30,138	31,293						27,375
General renewal period with provincial authorities	3 years	3 years
Period of expected cash flow	30 years	30 years

Intangible assets, net (Details 3) In Thousands, unless otherwise specified	Mar. 31, 2014 USD ($)	Mar. 31, 2014 CNY
Intangible assets, net
2015	$ 743	4,621
2016	743	4,621
2017	743	4,621
2018	743	4,621
2019 and thereafter	16,420	102,065
Total amortization expenses	$ 19,392	120,549

Available-for-sale equity securities (Details) In Thousands, unless otherwise specified	Mar. 31, 2014 USD ($)	Mar. 31, 2014 CNY	Mar. 31, 2013 CNY	Mar. 31, 2014 Life Corporation Limited - listed on Australian Securities Exchange USD ($)	Mar. 31, 2014 Life Corporation Limited - listed on Australian Securities Exchange CNY	Mar. 31, 2013 Life Corporation Limited - listed on Australian Securities Exchange CNY	Mar. 31, 2014 Cordlife Group Limited - listed on Singapore Exchange USD ($)	Mar. 31, 2014 Cordlife Group Limited - listed on Singapore Exchange CNY	Mar. 31, 2013 Cordlife Group Limited - listed on Singapore Exchange CNY
Schedule of Available-for-sale Securities
Total listed equity securities, at market	$ 23,204	144,247	88,404	$ 745	4,630	8,284	$ 22,459	139,617	80,120

Available-for-sale equity securities (Details 2) In Thousands, except Share data, unless otherwise specified	12 Months Ended				1 Months Ended	12 Months Ended									1 Months Ended		12 Months Ended
	Mar. 31, 2014 USD ($)	Mar. 31, 2014 CNY	Mar. 31, 2013 CNY	Mar. 31, 2012 CNY	Dec. 31, 2013 Life Corporation Limited (LFC)	Mar. 31, 2011 Life Corporation Limited (LFC) CNY	Mar. 31, 2009 Life Corporation Limited (LFC) CNY	Mar. 31, 2008 Life Corporation Limited (LFC) CNY	Mar. 31, 2014 Life Corporation Limited (LFC) USD ($)	Mar. 31, 2014 Life Corporation Limited (LFC) CNY	Mar. 31, 2013 Life Corporation Limited (LFC) CNY	Mar. 29, 2012 Life Corporation Limited (LFC)	Jun. 30, 2011 Life Corporation Limited (LFC)	Mar. 31, 2010 Life Corporation Limited (LFC)	Aug. 31, 2013 CGL (Cordlife Group Limited) SGD	Feb. 28, 2013 CGL (Cordlife Group Limited) SGD	Mar. 31, 2014 CGL (Cordlife Group Limited) CNY	Mar. 31, 2014 CGL (Cordlife Group Limited) SGD	Mar. 31, 2014 CGL (Cordlife Group Limited) USD ($)	Mar. 31, 2013 CGL (Cordlife Group Limited) CNY	Mar. 29, 2012 CGL (Cordlife Group Limited)	Jun. 30, 2011 CGL (Cordlife Group Limited)
Schedule of Available-for-sale Securities
Ordinary shares acquired						6,841,666	5,795,000	11,730,000
Cost to acquire ordinary shares						13,245	11,172	53,699
Ordinary shares held						24,366,666			8,122,222	8,122,222	24,366,666		24,366,666						24,366,666	24,366,666		24,366,666
Percentage equity interest owned						16.80%	18.90%	12.90%	11.40%	11.40%	14.10%	14.10%	16.10%	16.30%					9.20%	10.50%	10.50%	16.10%
Stock reverse-split ratio (as a percent)					0.33
Announced dividends per ordinary share															0.01	0.01
Dividend income	1,594	9,911	4,685	7,217													2,414	487
Cost basis of the available-for-sale equity securities	6,546	40,690	40,690
Total unrealized net holding gain (loss)									(1,050)	(6,527)	(3,024)						121,047		19,472	59,836
The aggregate fair values of the available-for-sale equity securities	23,204	144,247	88,404
Other-than-temporary impairment recognized in earnings		0	0
Accumulated other-than-temporary impairment recognized in earnings		37,426	37,426

Other investment (Details) In Thousands, unless otherwise specified	12 Months Ended				1 Months Ended			12 Months Ended
	Mar. 31, 2014 USD ($)	Mar. 31, 2014 CNY	Mar. 31, 2013 CNY	Mar. 31, 2012 CNY	Feb. 28, 2013 Qilu Stem Cells USD ($)	Feb. 28, 2013 Qilu Stem Cells CNY	May 31, 2010 Qilu Stem Cells	Mar. 31, 2014 Qilu Stem Cells USD ($)	Mar. 31, 2014 Qilu Stem Cells CNY	Mar. 31, 2013 Qilu Stem Cells CNY	Mar. 31, 2012 Qilu Stem Cells CNY
Schedule of Equity Method Investments [Line Items]
Percentage equity interest owned					24.00%	24.00%
Percentage equity interest acquired					4.08%	4.08%	19.92%
Cash paid for equity interest			54,766		$ 8,650	54,766
Unlisted equity securities, at cost	30,424	189,129	189,129
Dividend income	$ 1,594	9,911	4,685	7,217				$ 1,206	7,497	0	7,217

Bank loan (Details) (Short-term bank loan) In Thousands, unless otherwise specified						0 Months Ended
	Mar. 31, 2014	Aug. 12, 2013 USD ($)	Aug. 12, 2013 CNY	Mar. 31, 2013	Jul. 11, 2012 CNY	Jul. 11, 2012 People's Bank of China base lending rate
Bank loan
Amount borrowed		$ 9,652	60,000		50,000
Floating interest rate, percentage multiple						120.00%
Interest rate at period end				7.20%
Monthly fixed interest rate (as a percent)	0.60%

Accrued expenses and other payables (Details) In Thousands, unless otherwise specified	Mar. 31, 2014 USD ($)	Mar. 31, 2014 CNY	Mar. 31, 2013 CNY	Mar. 31, 2014 Convertible notes USD ($)	Mar. 31, 2014 Convertible notes CNY	Mar. 31, 2013 Convertible notes CNY
Debt Instrument
Insurance premiums received on behalf of an insurance company	$ 2,460	15,292	12,411
Other taxes payables	632	3,927	1,616
Accrued salaries, bonus and welfare expenses	3,701	23,005	17,828
Accrued consultancy and professional fees	579	3,599	7,770
Payable for convertible notes interests				4,213	26,188	26,639
Payable for debt issuance costs			3,242
Payable for property, plant and equipment	2,569	15,969
Other payables	2,344	14,579	14,500
Total accrued expenses and other payables	$ 16,498	102,559	84,006
Interest rate				7.00%	7.00%

Deferred revenue (Details) In Thousands, unless otherwise specified	Mar. 31, 2014 USD ($)	Mar. 31, 2014 CNY	Mar. 31, 2013 CNY	Mar. 31, 2014 Prepayments by customers prior to completion of cord blood processing services USD ($)	Mar. 31, 2014 Prepayments by customers prior to completion of cord blood processing services CNY	Mar. 31, 2013 Prepayments by customers prior to completion of cord blood processing services CNY	Mar. 31, 2014 Unearned storage fees USD ($)	Mar. 31, 2014 Unearned storage fees CNY	Mar. 31, 2013 Unearned storage fees CNY
Deferred revenue
Current portion	$ 31,599	196,432	172,328
Non-current portion	132,540	823,921	530,258
Total current and non-current deferred revenue	$ 164,139	1,020,353	702,586	$ 15,056	93,597	94,471	$ 149,083	926,756	608,115

Deferred revenue (Details 2) (Unearned storage fees) In Thousands, unless otherwise specified	12 Months Ended
	Mar. 31, 2014 USD ($)	Mar. 31, 2014 CNY	Mar. 31, 2013 CNY	Mar. 31, 2012 CNY
Analysis of unearned storage fees
Balance at beginning of year	$ 97,824	608,115	361,034	199,470
Deferred revenue arising from new customers	78,067	485,290	376,536	260,531
Credited to income	(26,808)	(166,649)	(129,455)	(98,967)
Balance at end of year	$ 149,083	926,756	608,115	361,034

Convertible notes (Details)	12 Months Ended		12 Months Ended				12 Months Ended
Convertible notes (Details)	Mar. 31, 2013 CNY	Mar. 31, 2014 Convertible notes	Mar. 31, 2014 Convertible notes KKR Notes	Mar. 31, 2013 Convertible notes KKR Notes USD ($)	Mar. 31, 2013 Convertible notes KKR Notes CNY	Apr. 27, 2012 Convertible notes KKR Notes USD ($)	Mar. 31, 2014 Convertible notes GMHL Notes Golden Meditech Holdings Limited (GMHL)	Mar. 31, 2013 Convertible notes GMHL Notes Golden Meditech Holdings Limited (GMHL) USD ($)	Mar. 31, 2013 Convertible notes GMHL Notes Golden Meditech Holdings Limited (GMHL) CNY	Oct. 03, 2012 Convertible notes GMHL Notes Golden Meditech Holdings Limited (GMHL) USD ($)
Debt Instrument
Aggregate principal amount						$ 65,000,000				$ 50,000,000
Interest rate		7.00%				7.00%				7.00%
Conversion price per share						$ 2.838				$ 2.838
Proceeds from issuance of convertible notes	730,493,000			65,000,000				50,000,000
Default interest rate		22.50%
Issuance costs incurred					14,260,000				4,258,000
Guaranteed internal rate of return			12.00%				12.00%
Threshold amount of new debt which must be approved						$ 22,000,000				$ 87,000,000

Convertible notes (Details 2) (Convertible notes) In Thousands, unless otherwise specified	Mar. 31, 2014 USD ($)	Mar. 31, 2014 CNY	Mar. 31, 2013 CNY	Mar. 31, 2014 KKR Notes USD ($)	Mar. 31, 2014 KKR Notes CNY	Mar. 31, 2013 KKR Notes CNY	Mar. 31, 2014 GMHL Notes Golden Meditech Holdings Limited (GMHL) USD ($)	Mar. 31, 2014 GMHL Notes Golden Meditech Holdings Limited (GMHL) CNY	Mar. 31, 2013 GMHL Notes Golden Meditech Holdings Limited (GMHL) CNY
Debt Instrument
Principal amount of Notes				$ 64,879	403,315	409,764
Principal amount of Notes							49,917	310,302	315,226
Cumulative interest payable	10,317	64,136	26,791
Carrying amount	$ 125,113	777,753	751,781

- Definition

Carrying amount of long-term debt, net of unamortized discount or premium, including current and noncurrent amounts. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.

+ References+ Details

- Definition

The amount for notes payable (written promise to pay), payable to related parties, which are due after one year (or one business cycle).

+ References+ Details

Convertible notes (Details 3) In Thousands, unless otherwise specified	12 Months Ended
	Mar. 31, 2014 USD ($)	Mar. 31, 2014 CNY	Mar. 31, 2013 CNY	Mar. 31, 2014 Golden Meditech Holdings Limited (GMHL) USD ($)	Mar. 31, 2014 Golden Meditech Holdings Limited (GMHL) CNY	Mar. 31, 2013 Golden Meditech Holdings Limited (GMHL) CNY	Mar. 31, 2014 Convertible notes USD ($)	Mar. 31, 2014 Convertible notes CNY	Mar. 31, 2013 Convertible notes CNY	Mar. 31, 2014 Convertible notes KKR Notes USD ($)	Mar. 31, 2014 Convertible notes KKR Notes CNY	Mar. 31, 2013 Convertible notes KKR Notes CNY	Mar. 31, 2014 Convertible notes GMHL Notes Golden Meditech Holdings Limited (GMHL) USD ($)	Mar. 31, 2014 Convertible notes GMHL Notes Golden Meditech Holdings Limited (GMHL) CNY	Mar. 31, 2013 Convertible notes GMHL Notes Golden Meditech Holdings Limited (GMHL) CNY
Debt Instrument
Notes interest incurred										$ 8,120	50,475	45,959
Notes interest incurred				6,112	37,994	18,761							6,112	37,994	18,761
Amortization of debt issuance costs	581	3,610	3,062				581	3,610	3,062
Convertible Notes Interest Cost Capitalization							(3,993)	(24,822)	(1,207)
Total interest expense							$ 10,820	67,257	66,575

Shareholders' equity (Details)	0 Months Ended			1 Months Ended		12 Months Ended
Shareholders' equity (Details)	Jul. 24, 2013 USD ($)	Aug. 03, 2011	Sep. 15, 2010 USD ($)	Nov. 30, 2012	Dec. 31, 2006 USD ($)	Mar. 31, 2014 USD ($)	Mar. 31, 2014 CNY	Mar. 31, 2013 CNY	Mar. 31, 2012 CNY	Jul. 31, 2012 USD ($)	Mar. 31, 2011	Mar. 31, 2014 Zhejiang Lukou CNY
Statement
Ordinary shares, shares outstanding						73,003,248	73,003,248	73,003,248	73,140,147		75,406,875
Purchase of Treasury Stock, shares								7,450,914
Purchase of Treasury Stock								131,302,000
Sale of treasury shares, shares				7,314,015				7,314,015
Treasury stock, shares						136,899	136,899	136,899
Shares repurchased and retired, total cost									44,664,000
Excess of repurchase price over par value of shares repurchased									44,662,000
Number of shares repurchased and retired									2,266,728
Share repurchase program	20,000,000		15,000,000							20,000,000
Share repurchase program, original period	12 months		1 year
Share repurchase program, refreshment period		12 months
Beijing Jiachenhong, Guangzhou Nuoya and Zhejiang Lukou required to transfer net income, percentage						10.00%	10.00%
The percentage of their respective registered capital that the statutory surplus reserve must reach before Beijing Jiachenhong, Guangzhou Nuoya and Zhejiang Lukou are not required to transfer their net income						50.00%	50.00%
The percent of registered capital that must be retained in the reserve balance after conversion into issued capital						25.00%	25.00%
Transfers made to the statutory surplus reserve by Beijing Jiachenhong and Guangzhou Nuoya						3,677,000	22,858,000	22,638,000	17,656,000
Accumulated statutory surplus reserve						$ 16,237,000	100,937,000	78,079,000				0
Exercise price of outstanding warrants					$ 5.00
Number of shares per unit					1
Number of IPO warrants per unit					2
Number of shares per warrant					1
Price of EBC option to purchase units					$ 0.1
Number of units available to be purchased through option					500,000
EBC option to purchase units, exercise price per unit					$ 6.60

Revenues Details In Thousands, unless otherwise specified	12 Months Ended
Revenues Details In Thousands, unless otherwise specified	Mar. 31, 2014 USD ($)	Mar. 31, 2014 CNY	Mar. 31, 2013 CNY	Mar. 31, 2012 CNY	Mar. 31, 2014 Cord Blood Processing Fees USD ($)	Mar. 31, 2014 Cord Blood Processing Fees CNY	Mar. 31, 2013 Cord Blood Processing Fees CNY	Mar. 31, 2012 Cord Blood Processing Fees CNY	Mar. 31, 2014 Cord Blood Storage Fees USD ($)	Mar. 31, 2014 Cord Blood Storage Fees CNY	Mar. 31, 2013 Cord Blood Storage Fees CNY	Mar. 31, 2012 Cord Blood Storage Fees CNY	Mar. 31, 2014 Fees Derived from the Provision of Donated Cord Blood for Transplantation and Research and Others USD ($)	Mar. 31, 2014 Fees Derived from the Provision of Donated Cord Blood for Transplantation and Research and Others CNY	Mar. 31, 2013 Fees Derived from the Provision of Donated Cord Blood for Transplantation and Research and Others CNY	Mar. 31, 2012 Fees Derived from the Provision of Donated Cord Blood for Transplantation and Research and Others CNY
Revenues from External Customers and Long-Lived Assets
Revenues	$ 92,152	572,857	526,123	380,490	$ 64,837	403,058	394,641	279,481	$ 26,808	166,649	129,455	98,967	$ 507	3,150	2,027	2,042

Income tax (Details) In Thousands, unless otherwise specified	12 Months Ended										60 Months Ended	75 Months Ended	12 Months Ended				75 Months Ended	33 Months Ended	12 Months Ended	51 Months Ended	21 Months Ended
	Mar. 31, 2014 USD ($)	Mar. 31, 2014 CNY	Mar. 31, 2013 CNY	Mar. 31, 2012 CNY	Mar. 31, 2014 PRC tax laws and rules USD ($)	Mar. 31, 2014 PRC tax laws and rules CNY	Dec. 31, 2012 PRC tax laws and rules	Dec. 31, 2011 PRC tax laws and rules	Dec. 31, 2010 PRC tax laws and rules	Dec. 31, 2009 PRC tax laws and rules	Dec. 31, 2012 PRC tax laws and rules	Mar. 31, 2014 PRC tax laws and rules	Mar. 31, 2014 Hong Kong Profits Tax CNY	Mar. 31, 2013 Hong Kong Profits Tax CNY	Mar. 31, 2012 Hong Kong Profits Tax CNY	Mar. 31, 2014 PRC subsidiary CNY	Mar. 31, 2014 Beijing Jiachenhong	Dec. 31, 2016 Beijing Jiachenhong Scenario forecast	Mar. 31, 2012 Guangzhou Nuoya CNY	Mar. 31, 2014 Guangzhou Nuoya	Dec. 31, 2015 Guangzhou Nuoya Scenario forecast
Income Tax
Tax provision	$ 9,394	58,398	38,543	9,634									0	0	0
Statutory income tax rate												25.00%
HNTE preferential tax rate												15.00%					15.00%	15.00%		15.00%	15.00%
New tax law transition period											5 years
Tax refund	69	429	408	10,433															10,433
Transitional tax rate							25.00%	24.00%	22.00%	20.00%
Withholding tax rate												10.00%
Provision for income taxes on undistributed earnings																0
Provision for withholding tax	627	3,900
Unremitted earnings that may be subject to the withholding tax	122,048	758,698
Unrecognized deferred tax liability from unremitted earnings of PRC subsidiaries	12,205	75,870
Interest and penalties related to unrecognized tax benefits		0	0	0
Statute of limitation, underpayment due to computational errors					3 years	3 years
Statute of limitation, special circumstances where underpayment is more than RMB100					5 years	5 years
Statute of limitation, transfer pricing issues					10 years	10 years
Underpayment of taxes threshold that extends the statute of limitation					$ 16	100

Income tax (Details 2) In Thousands, unless otherwise specified	12 Months Ended
	Mar. 31, 2014 USD ($)	Mar. 31, 2014 CNY	Mar. 31, 2013 CNY	Mar. 31, 2012 CNY
Income tax
The PRC	$ 50,982	316,933	260,462	179,654
Non-PRC	(20,270)	(126,009)	(102,277)	(28,055)
Income before income tax expense	$ 30,712	190,924	158,185	151,599

Income tax (Details 3) In Thousands, unless otherwise specified	12 Months Ended
	Mar. 31, 2014 USD ($)	Mar. 31, 2014 CNY	Mar. 31, 2013 CNY	Mar. 31, 2012 CNY
Income tax
Current tax expense	$ 8,043	50,000	38,737	14,405
Deferred income taxes	1,351	8,398	(194)	(4,771)
Actual income tax expense	$ 9,394	58,398	38,543	9,634

- Definition

Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.

+ References+ Details

- Definition

Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.

+ References+ Details

Income tax (Details 4) In Thousands, unless otherwise specified	12 Months Ended
	Mar. 31, 2014 USD ($)	Mar. 31, 2014 CNY	Mar. 31, 2013 CNY	Mar. 31, 2012 CNY
Income tax
Income before income tax expense	$ 30,712	190,924	158,185	151,599
Computed "expected" tax expense	7,678	47,731	39,546	37,900
Non-PRC entities not subject to income tax	5,068	31,502	25,569	7,014
PRC dividend withholding tax	1,590	9,887
Non-taxable income	(301)	(1,874)		(1,804)
Effect of change in tax rates				(14,674)
Tax rate differential, preferential rate	(4,667)	(29,011)	(26,015)	(19,779)
Others	26	163	(557)	977
Actual income tax expense	$ 9,394	58,398	38,543	9,634

Income tax (Details 5) In Thousands, unless otherwise specified	Mar. 31, 2014 USD ($)	Mar. 31, 2014 CNY	Mar. 31, 2013 CNY
Deferred tax assets:
Accounts receivable	$ 1,096	6,812	4,719
Non-current accounts receivable	1,030	6,406	5,754
Property, plant and equipment			1,616
Inventories	369	2,293	2,513
Tax loss			2,011
Others	197	1,226	798
Net deferred tax assets	2,692	16,737	17,411
Deferred tax liabilities:
Deferred revenue	(15)	(96)	(105)
Property, plant and equipment	(802)	(4,988)
Withholding tax	(627)	(3,900)
Intangible assets	(4,848)	(30,138)	(31,293)
Deferred tax liabilities	(6,292)	(39,122)	(31,398)
Net deferred tax liabilities	(3,600)	(22,385)	(13,987)
Classification on consolidated balance sheets
Current deferred tax assets	1,233	7,664	5,454
Current deferred tax liabilities	(627)	(3,900)
Non-current deferred tax assets	288	1,789	3,727
Non-current deferred tax liabilities	(4,494)	(27,938)	(23,168)
Net deferred tax liabilities	$ (3,600)	(22,385)	(13,987)

Share-based compensation (Details) (Restricted Share Unit, USD $) In Thousands, except Share data, unless otherwise specified	12 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2012
Restricted Share Unit
Share-based compensation
Limit on granting rights as a percentage of Company's issued and outstanding share capital	10.00%
Shares granted in period	0	0	0
Compensation expense for period	$ 0	$ 0	$ 0

Net income per share (Details) In Thousands, except Share data, unless otherwise specified	12 Months Ended
	Mar. 31, 2014 USD ($)	Mar. 31, 2014 CNY	Mar. 31, 2013 CNY	Mar. 31, 2012 CNY	Mar. 31, 2014 Convertible notes USD ($)	Mar. 31, 2014 Convertible notes CNY	Mar. 31, 2013 Convertible notes CNY
Net income per share
Interest rate					7.00%	7.00%
Numerator:
Net income attributable to the Company	$ 21,218	131,903	112,447	131,980
Earnings allocated to participating convertible notes					(2,421)	(15,050)	(6,053)
Net income for basic and diluted net income per share	$ 18,797	116,853	106,394	131,980
Denominator:
Weighted average ordinary shares outstanding for basic and diluted net income per share	73,003,248	73,003,248	71,527,698	73,897,177
Net income per share attributable to ordinary shares:
Basic	$ 0.26	1.60	1.49	1.79
Diluted	$ 0.26	1.60	1.49	1.79
Anti-dilutive ordinary shares					40,521,495	40,521,495	40,521,495

Related party transactions (Details) In Thousands, unless otherwise specified				1 Months Ended	12 Months Ended				57 Months Ended		12 Months Ended						12 Months Ended
	Mar. 31, 2014 USD ($)	Mar. 31, 2014 CNY	Mar. 31, 2013 CNY	Jun. 30, 2009 Beijing Jingjing CNY	Mar. 31, 2014 Beijing Jingjing USD ($)	Mar. 31, 2014 Beijing Jingjing CNY	Mar. 31, 2013 Beijing Jingjing CNY	Mar. 31, 2012 Beijing Jingjing CNY	Mar. 31, 2014 Beijing Jingjing USD ($)	Mar. 31, 2014 Beijing Jingjing CNY	Mar. 31, 2014 Golden Meditech Holdings Limited (GMHL) USD ($)	Mar. 31, 2014 Golden Meditech Holdings Limited (GMHL) CNY	Mar. 31, 2013 Golden Meditech Holdings Limited (GMHL) CNY	Mar. 31, 2014 GMHL, Beijing Jingjing and China Bright USD ($)	Mar. 31, 2014 GMHL, Beijing Jingjing and China Bright CNY	Mar. 31, 2013 GMHL, Beijing Jingjing and China Bright CNY	Mar. 31, 2014 China Bright Group Co. Limited USD ($)	Mar. 31, 2014 China Bright Group Co. Limited CNY	Mar. 31, 2014 Golden Meditech (S) Pte Ltd. USD ($)	Mar. 31, 2014 Golden Meditech (S) Pte Ltd. CNY	Mar. 31, 2014 Golden Meditech (S) Pte Ltd. SGD
Related Party Transaction
Rental of properties					$ 232	1,440	1,440	1,440											$ 145	904	200
Raw material purchase																	2,306	14,336
Interest expenses											6,112	37,994	18,761
Amounts due to related parties	3,452	21,453	11,241											3,452	21,453	11,241
Monthly rental payment				174					$ 19	120
Period of lease									5 years 6 months	5 years 6 months

- Definition

Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).

+ References+ Details

Pension and other postretirement benefits (Details) In Thousands, unless otherwise specified	12 Months Ended
	Mar. 31, 2014 USD ($)	Mar. 31, 2014 CNY	Mar. 31, 2013 CNY	Mar. 31, 2012 CNY
Pension and other postretirement benefits
Defined contribution rate based on a standard salary base	20.00%	20.00%
Defined contribution plan expense	$ 2,306	14,337	12,158	9,682

Fair value measurements (Details) In Thousands, unless otherwise specified	Mar. 31, 2014 Level 3 USD ($)	Mar. 31, 2014 Level 3 CNY	Mar. 31, 2014 Carrying value USD ($)	Mar. 31, 2014 Carrying value CNY
Fair value measurements
Fair value of convertible notes	$ 176,640	1,098,065
Carrying value of convertible notes			$ 125,113	777,753

Business and credit concentrations (Details) (Supplier, Purchases of raw materials) In Thousands, unless otherwise specified	12 Months Ended
	Mar. 31, 2014 USD ($)	Mar. 31, 2014 CNY	Mar. 31, 2013 CNY	Mar. 31, 2012 CNY	Mar. 31, 2014 Shanghai Qiangzhi Biological Technology Co., Ltd. USD ($)	Mar. 31, 2014 Shanghai Qiangzhi Biological Technology Co., Ltd. CNY	Mar. 31, 2013 Shanghai Qiangzhi Biological Technology Co., Ltd. CNY	Mar. 31, 2012 Shanghai Qiangzhi Biological Technology Co., Ltd. CNY	Mar. 31, 2013 Hangzhou Baitong Biological Technology Co., Ltd. CNY	Mar. 31, 2012 Hangzhou Baitong Biological Technology Co., Ltd. CNY	Mar. 31, 2014 Cesca Therapeutics Inc. USD ($)	Mar. 31, 2014 Cesca Therapeutics Inc. CNY	Mar. 31, 2014 China Bright Group Co. Limited USD ($)	Mar. 31, 2014 China Bright Group Co. Limited CNY	Mar. 31, 2012 Beijing Zhu You Ying Kang Technology Development Co., Ltd. CNY	Mar. 31, 2012 Beijing Probe Biological Technology Co., Ltd. CNY
Concentration Risk
Percentage of purchases	51.00%	51.00%	37.00%	62.00%	11.00%	11.00%	22.00%	11.00%	15.00%	16.00%	17.00%	17.00%	23.00%	23.00%	25.00%	10.00%
Purchases from suppliers	$ 5,207	32,372	18,935	20,838	$ 1,157	7,195	11,152	3,619	7,783	5,490	$ 1,744	10,841	$ 2,306	14,336	8,340	3,389

Commitments and contingencies (Details 2) In Thousands, unless otherwise specified	Mar. 31, 2014 USD ($)	Mar. 31, 2014 CNY
Commitments and contingencies
2015	$ 286	1,780
2016	25	156
2017	12	72
Total payments	$ 323	2,008

Commitments and contingencies (Details 3) In Thousands, unless otherwise specified						6 Months Ended		88 Months Ended	6 Months Ended		47 Months Ended	12 Months Ended
	Mar. 31, 2014 Research and development of medicines USD ($)	Mar. 31, 2014 Research and development of medicines CNY	Mar. 31, 2013 Research and development of medicines CNY	Mar. 31, 2014 Co-operation agreement USD ($)	Mar. 31, 2014 Co-operation agreement CNY	Mar. 31, 2014 Co-operation agreement Peking University People's Hospital USD ($)	Mar. 31, 2014 Co-operation agreement Peking University People's Hospital CNY	Sep. 30, 2013 Co-operation agreement Peking University People's Hospital CNY	Mar. 31, 2014 Co-operation agreement Guangdong Women and Children's Hospital and Health Institute USD ($)	Mar. 31, 2014 Co-operation agreement Guangdong Women and Children's Hospital and Health Institute CNY	Sep. 30, 2013 Co-operation agreement Guangdong Women and Children's Hospital and Health Institute CNY	Mar. 31, 2014 Co-operation agreement Zhejiang Provincial Blood Center USD ($)	Mar. 31, 2014 Co-operation agreement Zhejiang Provincial Blood Center CNY
Operating Lease, Contractual, and Capital Commitments
Commitment as of year end	$ 322	2,000	2,000	$ 16,178	100,567
Annual advisory fee						$ 418	2,600	2,000	$ 515	3,200	2,000	$ 322	2,000
Annual advisory fee, time period						20 years	20 years					3 years	3 years

Commitments and contingencies (Details 4) (Co-operation agreement) In Thousands, unless otherwise specified	Mar. 31, 2014 USD ($)	Mar. 31, 2014 CNY
Future minimum payments
2015	$ 933	5,800
2016	933	5,800
2017	933	5,800
2018	933	5,800
2019	933	5,800
2020 and thereafter	11,513	71,567
Total payments	$ 16,178	100,567

Summary of significant accounting policies (Details)	Mar. 31, 2014
Summary of significant accounting policies
Foreign currency convenience translation rate	6.2164